GVK_ID	DRUG_NAME	LAST_SIGNIFICANT_UPDATE	STATUS	REASON_WITHDRAWN	REMARKS	DRUG_DOSE	HIGHEST_PHASE_TRIAL	MODE_OF_ACTION	DATABASE_NAME	HIGHEST_PHASE_ALL	APPROVAL_DATE	STD_HIGHEST_PHASE_ALL	FLAG	COMPANY_NAME	GVK_ID_1	FLAG_1	APPROVAL_YEAR	LAST_SIGNIFICANT_UPDATE_YEAR
5900537	GEFITINIB	March 13, 2014	WITHDRAWN DRUG			For lung cancer, non-small cell:Adults--250 milligrams (mg) dailyChildren--Use and dose must be determined by doctor	Withdrawn	The mechanism of the clinical antitumor action of gefitinib is not fully characterized. Gefitinib inhibits the intracellular phosphorylation of numerous tyrosine kinases associated with transmembrane cell surface receptors, including the tyrosine kinases associated with the epidermal growth factor receptor (EGFR-TK)	DD	Withdrawn - Breast cancer, Renal cancer, Colorectal cancer, Glioblastoma, Leukemia, Non-small cell lung cancer, Solid Tumor; Launched - Breast cancer, Renal cancer, Colorectal cancer, Glioblastoma, Leukemia, Non-small cell lung cancer, Solid Tumor	May 05, 2003	Withdrawn; Launched		ASTRAZENECA	5900537	MAR14_4	2003	2014
5903170	FELODIPINE + ENALAPRIL		PRESCRIPTION DRUG				Launched	Enalapril is converted to enalaprilat which acts as angiotensin converting enzyme inhibitor. Felodipine is a dihydropyridine calcium channel blocker	DD	Launched - HYPERTENSION	December 27, 1996	Launched	APR11_2	AstraZeneca	5903170	APR11_2	1996	1995
5903244	VANDETANIB	March 13, 2014	PRESCRIPTION DRUG			300 mg once daily	Launched	Vascular endothelial growth factor receptor 2 inhibitor; Epidermal growth factor receptor tyrosine kinase inhibitor	DD	Launched - Metastatic thyroid cancer	April 06, 2011	Launched	AUG11_3	ASTRAZENECA	5903244	MAR14_4	2011	2014
5910042	ZD 3523	February 12, 2014					Discontinued	Leukotriene D4 receptor antagonist; Leukotriene E4 receptor antagonist	CCD	Phase III - Asthma, Allergic rhinitis; Discontinued - Asthma, Allergic rhinitis		Phase III; Discontinued		ASTRAZENECA	5910042	MAR14_4	1995	2014
5910117	BUCINDOLOL	July 12, 2013					Discontinued	Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist	CCD	Discontinued - Congestive heart failure, Hypertension; Phase III - Congestive heart failure, Hypertension		Discontinued; Phase III		ASTRA MERCK INC	5910117		1995	2013
5910129	CANGRELOR	August 14, 2015	Prescription Drug	TMC halts phase III cangrelor program for PCI due to lack of efficacy		Administer 30 ug/kg intravenous bolus prior to PCI followed immediately by a 4 ug/kg/min intravenous infusion for at least 2 hours or duration of procedure, whichever is longer	Launched	P2Y12 purinoceptor antagonist; Platelet ADP receptor antagonist; Platelet aggregation inhibitor	DD	Launched - Periprocedural myocardial infarction, Repeated coronary revascularization, Stent thrombosis; Phase III - Coronary artery disease, Coronary thrombosis	June 22, 2015	Launched; Phase III		ASTRAZENECA PLC	5910129		2015	2015
5912261	ARC 67085	May 12, 2015					Discontinued	P2Y Purinoceptor 12 antagonist; P2Y Purinoceptor 11 agonist; P2Y Purinoceptor 13 antagonist	CCD	Discontinued - Thrombosis; Phase II - Thrombosis		Discontinued; Phase II		ASTRAZENECA	5912261		1995	2015
5910409	ZD 0473	July 15, 2015		Due to its financial situation, Poniard terminated all of its employees & discontineud development of picoplatin			Discontinued	DNA synthesis inhibitor	CCD	Discontinued - Small cell lung cancer; Phase III - Small cell lung cancer; Phase II - Prostate tumor, Colorectal tumor		Discontinued; Phase III; Phase II		ASTRAZENECA PLC	5910409		1995	2015
5910214	LANICEMINE	November 17, 2014					Discontinued	NMDA receptor antagonist	CCD	Phase II - TREATMENT RESISTANT DEPRESSION; Discontinued - TREATMENT RESISTANT DEPRESSION		Discontinued; Phase II		ASTRAZENECA PLC	5910214		1995	2014
5910352	LONAPALENE	5/27/2002					Discontinued	5-Lipoxygenase inhibitor; Arachidonic acid antagonist	CCD	Discontinued - Psoriasis		Discontinued		ASTRA AB	5910352		1995	2002
5910352	LONAPALENE	5/27/2002					Discontinued	5-Lipoxygenase inhibitor; Arachidonic acid antagonist	CCD	Discontinued - Psoriasis		Discontinued		ASTRAZENECA	5910352		1995	2002
5910371	SIBENADET	March 27, 2007					Discontinued	Beta-2 adrenergic receptor agonist; Dopamine receptor D2 agonist	CCD	Discontinued - Cardiovascular disease, Asthma, Chronic obstructive pulmonary disease; Phase 3 - Chronic obstructive pulmonary disease; Phase 2 - Chronic obstructive pulmonary disease; Phase 1 - Cardiovascular disease, Asthma		Discontinued; Phase III; Phase II; Phase I		ASTRAZENECA PHARMACEUTICALS	5910371		1995	2007
5911062	PRECLAMOL	10/30/2006					Phase II	Dopamine receptor D2 partial agonist	CCD	Phase II - Schizophrenia		Phase II		ASTRAZENECA	5911062		1995	2006
5911421	CB 300179	8/9/2000					No Development	Thymidylate synthase inhibitor	CCD	Discontinued - Cancer; No Development - Cancer		Discontinued; No Development		ASTRAZENECA	5911421		1995	2000
5911449	ZM 214888	9/23/1999					Discontinued	Thymidylate synthase inhibitor	CCD	Discontinued - Leukemia		Discontinued		ASTRAZENECA	5911449		1995	1999
5910681	INOGATRAN	August 16, 2005					Discontinued	Factor IIa antagonist; Platelet aggregation inhibitor; Coagulation inhibitor	CCD	Discontinued - Angina		Discontinued		ASTRA AB (ASTRAZENECA PLC)	5910681		1995	2005
5910681	INOGATRAN	August 16, 2005					Discontinued	Factor IIa antagonist; Platelet aggregation inhibitor; Coagulation inhibitor	CCD	Discontinued - Angina		Discontinued		ASTRA AB	5910681		1995	2005
5910688	SAMERIDINE	June 26, 2005		The compound had been discontinued because it did not meet the efficacy required in the clinic			Discontinued	Opioid receptor mu agonist	CCD	Discontinued - Topical anesthesia		Discontinued		ASTRA AB (ASTRAZENECA PLC)	5910688		1995	2005
5910688	SAMERIDINE	June 26, 2005		The compound had been discontinued because it did not meet the efficacy required in the clinic			Discontinued	Opioid receptor mu agonist	CCD	Discontinued - Topical anesthesia		Discontinued		ASTRA AB	5910688		1995	2005
5910239	PONALRESTAT	10/6/1998					Discontinued	Aldose reductase inhibitor	CCD	Discontinued - Diabetic complications		Discontinued		ASTRAZENECA	5910239		1995	1998
5910397	PLEVITREXED	July 15, 2015					No Development	Thymidylate synthase inhibitor; Folate synthesis inhibitor	CCD	No Development - Gastric cancer, Ovarian cancer, Pancreatic cancer; Phase II - Solid tumor, Stomach tumor; Discontinued - Colorectal tumor, Solid tumor, Pancreas tumor, Stomach tumor		No Development; Phase II; Discontinued		ASTRAZENECA PLC	5910397		1995	2015
5911106	ICI 207828	9/6/2000					Discontinued	Antihypertensive; Diuretic	CCD	Discontinued - Hypertension		Discontinued		ASTRAZENECA	5911106		1995	2000
5911295	FPL 66096	1/13/2004					Discontinued	P2T receptor antagonist; Adenylate cyclase modulator; Adenosine receptor antagonist; Platelet aggregation inhibitor; Glycoprotein IIb/IIIa fibrinogen receptor antagonist; Coagulation inhibitor	CCD	Discontinued - Thrombosis		Discontinued		ASTRAZENECA R&D CHARNWOOD	5911295		1995	2004
5910811	ZD 1611	October 23, 2007					Discontinued	Endothelin A receptor antagonist	CCD	Discontinued - Chronic Obstructive Pulmonary Disease, Hypertension, Cardiovascular disease, Heart disease		Discontinued		ASTRAZENECA PLC	5910811		1995	2007
5911997	UH 232	June 15, 2015					Discontinued	Dopamine receptor D3 antagonist	CCD	Discontinued - Psychotic disorder; Phase I - Psychotic disorder		Discontinued; Phase I		ASTRA AB	5911997		1995	2015
5911998	AJ 76	June 15, 2015					No Development	Dopamine receptor D3 antagonist; Dopamine receptor D2 agonist	CCD	No Development - Schizophrenia; Preclinical - Schizophrenia		No Development; Preclinical		ASTRA ARCUS AB	5911998		1995	2015
5911470	BCH-2687	1/27/2003		Discontinued due to trial results which were not sufficiently strong to justify large-scale phase II studies			Discontinued	Opioid receptor mu 1 agonist	CCD	Discontinued - Pain		Discontinued		ASTRAZENECA	5911470		1995	2003
5912184	AH 13205	2/15/2006					Discontinued	Prostaglandin EP2 receptor agonist	CCD	Discontinued - Asthma		Discontinued		ASTRA R&D CHARNWOOD	5912184		1995	2006
5910703	ROBALZOTAN	October 08, 2009					Discontinued	5-Hydroxytryptamine 1A receptor antagonist	CCD	Discontinued - Anxiety disorders, Major depressive disorder		Discontinued		ASTRA ZENECA PLC	5910703		1995	2009
5910706	ZD 6169	August 6, 2013					Discontinued	Potassium channel agonist	CCD	Discontinued - Urinary incontinence; Phase II - Urinary incontinence		Discontinued; Phase II		ASTRA ZENECA	5910706		1995	2013
5910706	ZD 6169	August 6, 2013					Discontinued	Potassium channel agonist	CCD	Discontinued - Urinary incontinence; Phase II - Urinary incontinence		Discontinued; Phase II		ASTRAZENECA PLC	5910706		1995	2013
5910710	ZD 9379	August 7, 2013					Discontinued	Ionotropic glutamate receptor NMDA antagonist	CCD	Discontinued - Ischemic stroke, Pain; Phase II - Ischemic stroke, Pain		Discontinued; Phase II		ASTRAZENECA PLC	5910710		1995	2013
5910721	ZD 8321	3/24/2004					Discontinued	Neutrophil elastase inhibitor	CCD	Phase II - Respiratory distress syndrome; Phase I - chronic obstructive pulmonary disease, Peripheral vascular disease; Preclinical - Bronchitis, Cardiac failure, Peripheral vascular disease, Pulmonary disease, Respiratory distress syndrome; Discontinued - Bronchitis, Cardiac failure, Peripheral vascular disease, Pulmonary disease, Respiratory distress syndrome		Phase II; Phase I; Preclinical; Discontinued		ASTRAZENECA PLC	5910721		1995	2004
5910722	ROFLEPONIDE	August 7, 2013		Development of this formulation had been discontinued as the findings in the phase II studies showed that the product was not substantially better than the marketed intranasal steroid medications			Discontinued	Steroid hormone receptor agonist	CCD	Discontinued - Asthma, Inflammatory bowel disease, Rhinitis; Phase II - Asthma, Rhinitis; Phase I - Inflammatory bowel disease		Discontinued; Phase II; Phase I		ASTRAZENECA PLC	5910722		1995	2013
5910279	RACLOPRIDE	December 09, 2009					Discontinued	Dopamine receptor D2 antagonist; Antipsychotic	CCD	Discontinued - Psychotic disorder		Discontinued		ASTRAZENECA	5910279		1995	2009
5910279	RACLOPRIDE	December 09, 2009					Discontinued	Dopamine receptor D2 antagonist; Antipsychotic	CCD	Discontinued - Psychotic disorder		Discontinued		ASTRA AB (ASTRAZENECA PLC)	5910279		1995	2009
5910289	ISAMOLTAN	4/7/1999					Discontinued	Beta adrenergic receptor antagonist; 5-Hydroxytryptamine 1B receptor antagonist	CCD	Discontinued - Anxiety disorders		Discontinued; Phase III		ASTRAZENECA	5910289		1995	1999
5911158	ICI 147798	9/6/2000					Discontinued	Beta adrenergic receptor antagonist	CCD	Discontinued - Hypertension		Discontinued		ASTRAZENECA	5911158		1995	2000
5910827	AZD 2563	November 18, 2004					Discontinued	Protein 30S ribosomal subunit inhibitor	CCD	Discontinued - Gram positive bacterium infection		Discontinued		ASTRAZENECA PLC	5910827		1995	2004
5912059	GEA 857	4/7/1999					No Development	Potassium channel blocker	CCD	No Development - Cognition disorder, Depression		No Development		ASTRAZENECA	5912059		1995	1999
5911502	ICI 215918	4/7/1999					Discontinued	Aldose reductase inhibitor	CCD	Discontinued - Diabetic complications		Discontinued		ASTRAZENECA	5911502		1995	1999
5911537	FPL 13210	9/21/2000					Discontinued	Antiarrhythmic	CCD	Discontinued - Arrhythmias		Discontinued		ASTRAZENECA	5911537		1995	2000
5910167	ZD 7114	July 06, 2007					Discontinued	Energy metabolism modulator; Beta-3 adrenergic receptor agonist	CCD	Discontinued - Obesity, Non-insulin dependent diabetes; Preclinical - Obesity, Non-insulin dependent diabetes		Discontinued; Preclinical		ASTRAZENECA	5910167		1995	2007
5912030	FPL 66564	4/15/2002					No Development	Angiotensin converting enzyme inhibitor	CCD	No Development - Hypertension		No Development		ASTRAZENECA R&D CHARNWOOD	5912030		1995	2002
5910583	P 1075	1/15/2003		Development was discontinued following disappointing clinical results			Discontinued	Sarcolemmal ATP-sensitive K (sarcKATP) channel activator	CCD	Discontinued - Alopecia, Cardiovascular disease; Discontinued - Arrhythmias, Ischemic heart disorders		Discontinued		ASTRAZENECA	5910583		1995	2003
5910606	FLAVODILOL	September 13, 2013					Discontinued	Beta adrenergic receptor antagonist	CCD	Discontinued - Hypertension; Phase II - Hypertension		Discontinued; Phase II		ASTRA ZENECA	5910606		1995	2013
5910618	FOSOPAMINE	9/6/2000					Discontinued	Dopamine receptor D1 agonist	CCD	Discontinued - Hypertension		Discontinued		ASTRA ZENECA	5910618		1995	2000
5910332	CEFCANEL DALOXATE	July 15, 2013					Discontinued	Cell wall synthesis inhibitor	CCD	Discontinued - Bacterial infection; Phase III - Bacterial infection		Discontinued; Phase III		ASTRAZENECA	5910332		1995	2013
5910332	CEFCANEL DALOXATE	July 15, 2013					Discontinued	Cell wall synthesis inhibitor	CCD	Discontinued - Bacterial infection; Phase III - Bacterial infection		Discontinued; Phase III		ASTRA AB	5910332		1995	2013
5911036	U 27391	8/12/1994					Discontinued	Matrix metalloproteinase inhibitor; Collagenase inhibitor	CCD	Discontinued - Rheumatoid arthritis		Discontinued		ASTRAZENECA	5911036		1995	1994
5911180	ICI 206970	9/6/2000					Discontinued	Calcium channel blocker	CCD	Discontinued - Heart failure, Hypertension		Discontinued		ASTRAZENECA	5911180		1995	2000
5910875	ICI 185282	9/6/2000					Discontinued	Thromboxane A2 receptor antagonist	CCD	Discontinued - Arrhythmias		Discontinued		ASTRAZENECA	5910875		1995	2000
5915032	ICI 222155	7/4/1999					No Development	Aldose reductase inhibitor	CCD	No Development - Diabetic neuropathy		No Development		ASTRAZENECA	5915032		1995	1999
5914445	H 39484	1/5/2006					No Development	Neuropeptide Y receptor 1 antagonist	CCD	No Development - Heart disease, Hypertension		No Development		ASTRAZENECA PLC	5914445		1995	2006
5914638	NU-2058	2/16/2007					Preclinical	CDK1 inhibitor; CDK2 inhibitor	CCD	Preclinical - Cancer		Preclinical		ASTRAZENECA PLC	5914638		1995	2007
5914641	NU 6027	June 15, 2015					No Development	CDK1 inhibitor; CDK2 inhibitor	CCD	No Development - Cancer; Preclinical - Cancer		No Development; Preclinical		ASTRAZENECA PLC	5914641		1995	2015
5912759	FLA 57	4/7/1999					No Development	Dopamine beta hydroxylase inhibitor	CCD	No Development - Alcoholism		No Development		ASTRA ARCUS AB	5912759		1995	1999
5912760	HW 165	5/8/2002					No Development	Dopamine receptor agonist	CCD	No Development - Parkinson's disease, Schizophrenia, Psychosis		No Development		ASTRA AB	5912760		1995	2002
5914285	FPL 15765	7/4/1999					No Development	NMDA receptor antagonist	CCD	No Development - Pain		No Development		ASTRAZENECA	5914285		1995	1999
5914682	Q-85	8/29/2000					No Development	Hypoxia-selective agent	CCD	No Development - Cancer		No Development		ASTRAZENECA	5914682		1995	2000
5913101	AZD 0947	8/2/2006					Discontinued	Potassium channel activator	CCD	Discontinued - Overactive bladder		Discontinued; Phase II		ASTRAZENECA PLC	5913101		1995	2006
5913106	AZD-8129	11/8/2005					Discontinued	5-Hydroxytryptamine 1B receptor antagonist	CCD	Discontinued - Anxiety disorders; Major depressive disorder		Discontinued		ASTRAZENECA PLC	5913106		1995	2005
5913232	CEDIRANIB	March 28, 2016					Phase III	Vascular endothelial growth factor receptor Inhibitor	CCD	Phase III - OVARIAN CANCER; Discontinued - GLIOBLASTOMA, NON-SMALL CELL LUNG CANCER, COLORECTAL CARCINOMA		Phase III; Discontinued		ASTRAZENECA	5913232	APR16	1995	2016
5913232	CEDIRANIB	March 28, 2016					Phase III	Vascular endothelial growth factor receptor Inhibitor	CCD	Phase III - OVARIAN CANCER; Discontinued - GLIOBLASTOMA, NON-SMALL CELL LUNG CANCER, COLORECTAL CARCINOMA		Phase III; Discontinued		ASTRAZENECA PLC	5913232		1995	2016
5913232	CEDIRANIB	March 28, 2016					Phase III	Vascular endothelial growth factor receptor Inhibitor	CCD	Phase III - OVARIAN CANCER; Discontinued - GLIOBLASTOMA, NON-SMALL CELL LUNG CANCER, COLORECTAL CARCINOMA		Phase III; Discontinued		ASTRAZENECA PLC	5913232		1995	2016
5917904	AZD-1279	February 1, 2008					No Development	Antibacterial	CCD	No Development - Bacterial infection; Preclinical - Bacterial infection		No Development; Preclinical		ASTRAZENECA PLC	5917904		1995	2008
5914717	NAS 181	12/15/2005					No Development	5-Hydroxytryptamine 1B receptor antagonist	CCD	No Development - Major depressive disorder		No Development		ASTRAZENECA PLC	5914717		1995	2005
5910054	NITRONAPROXEN	January 28, 2015	PRESCRIPTION DRUG			Recommended doses are 375 mg and 750 mg	Launched	CYCLOOXYGENASE INHIBITOR; NITRIC OXIDE DONOR	DD	Launched - DUCHENNE MUSCULAR DYSTROPHY	September 11, 2013	Launched		ASTRAZENECA PLC	5910054		2013	2015
5913136	ZD 6126	June 15, 2015					Phase II	Angiogenesis inhibitor; Tubulin antagonist	CCD	Phase II - Solid tumour		Phase II		ASTRAZENECA PLC	5913136		1995	2015
5913630	UH 301	5/28/2002					No Development	5-Hydroxytryptamine 1A receptor antagonist	CCD	No Development - Anxiety disorders		No Development		ASTRAZENECA	5913630		1995	2002
5913636	2-BFI	4/3/2003					No Development	Imidazoline receptor agonist	CCD	No Development - Pain		No Development		ASTRAZENECA	5913636		1995	2003
5914201	H 142	7/4/1999					Discontinued	Renin inhibitor	CCD	Discontinued - Heart failure, Hypertension		Discontinued		ASTRAZENECA	5914201		1995	1999
5914202	H 29051	10/19/2004					No Development	Lipid peroxidation inhibitor	CCD	No Development - Myocardial infarction, Reperfusion injury		No Development		ASTRA HASSLE AB	5914202		1995	2004
5912887	TESAGLITAZAR	February 14, 2013					Discontinued	Peroxisome proliferator-activated receptor alpha agonist; Peroxisome proliferator-activated receptor gamma agonist	CCD	Discontinued - Type II diabetes mellitus		No Development; Discontinued		ASTRAZENECA PLC	5912887		1995	2013
5912888	DISUFENTON	2/22/2007					Discontinued	Free radical scavenger	CCD	Discontinued - Brain hemorrhage, Cerebrovascular ischemia, Neurodegenerative diseases		Discontinued		ASTRAZENECA PLC	5912888		1995	2007
5910148	REMACEMIDE	January 11, 2010					Discontinued	NMDA receptor antagonist	CCD	Phase 3 - Huntingtons chorea, Epilepsy; Phase 2 - Cerebrovascular ischemia, Huntingtons chorea, Parkinson's disease, Epilepsy; Discontinued - Alzheimer's disease, Cerebrovascular ischemia, Epilepsy, Huntingtons chorea, Parkinson's disease; Discovery - Alzheimer's disease, Huntingtons chorea		Phase III; Phase II; Discontinued; Discovery		ASTRAZENECA R&D CHARNWOOD	5910148		1995	2010
5910148	REMACEMIDE	January 11, 2010					Discontinued	NMDA receptor antagonist	CCD	Phase 3 - Huntingtons chorea, Epilepsy; Phase 2 - Cerebrovascular ischemia, Huntingtons chorea, Parkinson's disease, Epilepsy; Discontinued - Alzheimer's disease, Cerebrovascular ischemia, Epilepsy, Huntingtons chorea, Parkinson's disease; Discovery - Alzheimer's disease, Huntingtons chorea		Phase III; Phase II; Discontinued; Discovery		ASTRAZENECA PLC	5910148		1995	2010
5910148	REMACEMIDE	January 11, 2010					Discontinued	NMDA receptor antagonist	CCD	Phase 3 - Huntingtons chorea, Epilepsy; Phase 2 - Cerebrovascular ischemia, Huntingtons chorea, Parkinson's disease, Epilepsy; Discontinued - Alzheimer's disease, Cerebrovascular ischemia, Epilepsy, Huntingtons chorea, Parkinson's disease; Discovery - Alzheimer's disease, Huntingtons chorea		Phase III; Phase II; Discontinued; Discovery		ASTRAZENECA R & D CHARNWOOD	5910148		1995	2010
5910161	ALAPROCLATE	4/7/1999					Discontinued	5-Hydroxytryptamine transporter antagonist	CCD	Discontinued - Depression		Discontinued; Phase II		ASTRAZENECA	5910161		1995	1999
5913173	BANOXANTRONE	May 09, 2012					Discontinued	DNA topoisomerase II inhibitor	CCD	Discontinued - Cancer, Esophagus tumor, Acute lymphoblastic leukemia, Chronic lymphoid leukemia, Glioblastoma multiforme, Non-Hodgkin's lymphoma; Phase II - Chronic lymphocytic leukemia, Non-Hodgkin lymphoma, Brain tumor; Phase I - Solid tumor; Preclinical - Acute lymphoblastic leukemia		Discontinued; Phase II; Phase I; Preclinical		ASTRAZENECA PLC	5913173		1995	2012
5913686	BAFILOMYCIN A1	9/8/2000					No Development	Vacuolar H+ ATPase inhibitor	CCD	No Development - Cancer, Gastrointestinal disorders, Influenza virus infections, Postmenopausal osteoporosis		No Development		ASTRAZENECA	5913686		1995	2000
5913690	SUCCINOBUCOL	April 23, 2012					Discontinued	Vascular cell adhesion molecule 1 inhibitor	CCD	Discontinued - Atherosclerosis; Phase III - Atherosclerosis; Phase II - Restenosis; No Development - Hypercholesterolemia; Preclinical - Non-insulin dependent diabetes		Discontinued; Phase III; Phase II; No Development; Preclinical		ASTRAZENECA PLC	5913690		1995	2012
5914426	QUILOSTIGMINE	5/4/2002					Discontinued	Acetylcholinesterase inhibitor	CCD	Discontinued - Alzheimer's disease, Dementia		Discontinued		ASTRA AB	5914426		1995	2002
5914427	QX 314	3/28/2000					No Development	Sodium channel blocker	CCD	No Development - Pain		No Development		ASTRAZENECA	5914427		1995	2000
5913867	EBALZOTAN	3/5/2002					Discontinued	5-Hydroxytryptamine 1A receptor agonist	CCD	Discontinued - Major depressive disorder		Discontinued		ASTRA AB	5913867		1995	2002
5917853	AZD6703	2/8/2007					Discontinued	p38 MAP kinase inhibitor	CCD	Discontinued - Rheumatoid arthritis; Phase I - Rheumatoid arthritis		Discontinued; Phase I		ASTRAZENECA PLC	5917853		1995	2007
5917858	KU-58050	2/16/2007					Preclinical	ATM Kinase Inhibitor; Serine-threonine kinase receptor inhibitor	CCD	Preclinical - Cancer, Retrovirus infection		Preclinical		ASTRAZENECA PLC	5917858		1995	2007
5916050	SUSALIMOD	1/17/2002					No Development	TNF production inhibitor	CCD	No Development - Inflammatory bowel disease, Rheumatic disorders		No Development		ASTRAZENECA	5916050		1995	2002
5916808	LY 41	7/6/2001					No Development	5-Hydroxytryptamine 1A receptor agonist	CCD	No Development - Anxiety disorders, Depression		No Development		ASTRAZENECA	5916808		1995	2001
5916405	ALMOKALANT	7/13/1999		Discontinued on the basis of published results of a toxicokinetic study			Discontinued	Potassium channel blocker	CCD	Discontinued - Heart arrhythmia		Discontinued; Phase III		ASTRA AB	5916405		1995	1999
5916649	AZD0424	August 2, 2010					No Development	Src tyrosine kinase inhibitor	CCD	No Development - Solid tumor; Preclinical - Solid tumor		No Development; Preclinical		ASTRAZENECA PLC	5916649		1995	2010
5916650	AZD-0530	September 18, 2015					Phase III	Src tyrosine kinase inhibitor; Abl tyrosine kinase inhibitor	CCD	Phase III - Ovarian cancer, Metastatic colorectal cancer; Discontinued - Ovarian cancer; Phase II - Colorectal tumor, Breast cancer, Prostate cancer, Bone neoplasm, Osteosarcoma, Colorectal cancer, Pancreatic cancer, Thymic carcinoma, Endometrial cancer, Skin melanoma, Head and neck cancer, Squamous cell carcinoma, Verrucous carcinoma, Tongue cancer; Phase I - Hematological disease		Phase III; Discontinued; Phase II; Phase I		ASTRAZENECA PLC	5916650		1995	2015
5917010	ARL 67974	5/27/2002					No Development	Phospholipase A2 inhibitor	CCD	No Development - Inflammation		No Development		ASTRA LTD	5917010		1995	2002
5917557	AZD-6942	June 11, 2005		Due to a difficult synthesis process and a short half life the compound has been discontinued			Discontinued	C-C chemokine receptor 2 antagonist	CCD	Discontinued - Rheumatoid arthritis		Discontinued		ASTRAZENECA PLC	5917557		1995	2005
5916453	ZD-4190	9/22/2006		Discontinued owing to results in healthy volunteers showing that it had a very long half life in phase I trials			Discontinued	VEGFR inhibitor; Tyrosine Kinase Inhibitor	CCD	Discontinued - Solid tumor		Discontinued		ASTRAZENECA PLC	5916453		1995	2006
5917175	ZM447439	April 09, 2015					No Development	AURORA KINASE A INHIBITOR; AURORA KINASE B INHIBITOR	CCD	No Development - CANCER; Phase I - CANCER		No Development; Phase I		ASTRAZENECA PLC	5917175	JUN14_4	1995	2015
5917175	ZM447439	April 09, 2015					No Development	AURORA KINASE A INHIBITOR; AURORA KINASE B INHIBITOR	CCD	No Development - CANCER; Phase I - CANCER		No Development; Phase I		ASTRAZENECA	5917175		1995	2015
5917183	ISPRONICLINE	October 01, 2013					Phase II	Nicotinic acetylcholine receptor alpha4 beta2 partial agonist	CCD	Phase II - Alzheimer's disease, Attention deficit hyperactivity disorder, Age-associated memory impairment, Schizophrenia; Discontinued - Schizophrenia		Phase II		ASTRAZENECA PLC	5917183		1995	2013
5917885	AZD-3043	June 15, 2015					Discontinued	GABAA receptor modulator	CCD	Discontinued - Anesthesia; Phase I - Anesthesia		Discontinued; Phase I		ASTRAZENECA PLC	5917885		1995	2015
5918063	AZD-6610	December 24, 2013					Discontinued	Peroxisome proliferator-activated receptor alpha partial agonist; Peroxisome proliferator-activated receptor gamma agonist	CCD	Discontinued - Dyslipidemia; Phase I - Dyslipidemia		Discontinued; Phase I		ASTRAZENECA PLC	5918063		1995	2013
5918064	AZD-8677	December 26, 2013					Discontinued	Lipid metabolism modulator	CCD	Discontinued - Diabetes mellitus, Dyslipidemia; Phase I - Lipid metabolism disorder, Diabetes mellitus		Discontinued; Phase I		ASTRAZENECA PLC	5918064		1995	2013
5918065	AZD-2327	May 15, 2012					Discontinued	Opioid receptor delta 1  agonist	CCD	Discontinued - Anxiety, Depression; Phase I - Anxiety disorder, Major depressive disorder		Discontinued; Phase I	JAN12_3	ASTRAZENECA PLC	5918065	JAN12_3	1995	2012
5915693	ZD 0892	3/24/2004					Discontinued	Elastase inhibitor	CCD	Discontinued - Asthma, Chronic Obstructive Pulmonary Disease, Peripheral vascular disorders		Discontinued		ASTRAZENECA PLC	5915693		1995	2004
5915694	ZD 2767P	8/9/2003					Discontinued	Anticancer; Immunotoxin	CCD	Discontinued - Solid tumor, Colorectal tumor; No Development - Solid tumor		Discontinued; No Development		ASTRAZENECA	5915694		1995	2003
5915707	ARA 014418	June 15, 2015					Discontinued	Glycogen synthase kinase 3 inhibitor	CCD	Discontinued - Alzheimer's disease, Major depressive disorder; Preclinical - Alzheimer's disease, Major depressive disorder		Discontinued; Preclinical		ASTRAZENECA AB	5915707		1995	2015
5915720	ZM 226600	7/4/1999					No Development	Potassium channel agonist	CCD	No Development - Urinary incontinence		No Development		ASTRAZENECA	5915720		1995	1999
5916860	FRAKEFAMIDE	5/6/2005		Discontinued due to a lack of efficacy			Discontinued	Opioid receptor mu agonist	CCD	Discontinued - Pain		Discontinued		ASTRAZENECA PLC	5916860		1995	2005
5915729	ARM 390	6/12/2002					No Development	Opioid receptor delta agonist	CCD	No Development - Pain		No Development		ASTRAZENECA	5915729		1995	2002
5915730	ARM 434	12/18/2003					No Development	Opioid receptor delta agonist	CCD	No Development - Pain; Preclinical - Pain		No Development; Preclinical		ASTRAZENECA	5915730		1995	2003
5915731	ARR 15849	8/10/2001					No Development	Cholecystokinin A receptor agonist	CCD	No Development - Obesity		No Development		ASTRA ARCUS USA	5915731		1995	2001
5915732	ARR 17477	10/31/2005					No Development	Nitric oxide synthase inhibitor	CCD	No Development - Reperfusion injury, Inflammation, Ischemia		No Development		ASTRA ARCUS USA	5915732		1995	2005
5915732	ARR 17477	10/31/2005					No Development	Nitric oxide synthase inhibitor	CCD	No Development - Reperfusion injury, Inflammation, Ischemia		No Development		ASTRAZENECA R&D CHARNWOOD	5915732		1995	2005
5915733	ARR 17779	7/4/1999					No Development	Nicotinic acetylcholine receptor alpha7 agonist	CCD	No Development - Anxiety disorders, Cognition disorder		No Development		ASTRA ARCUS USA	5915733		1995	1999
5916507	AZM-475271	12/11/2006					No Development	Src tyrosine kinase inhibitor	CCD	No Development - Cancer; Preclinical - Cancer		No Development; Preclinical		ASTRAZENECA PLC	5916507		1995	2006
5917187	AZD-6244	June 30, 2015					Phase III	MEK1 protein kinase inhibitor; MEK2 inhibitor	CCD	Phase III - KRAS mutant non-small cell lung cancer, Thyroid cancer, Uveal melanoma; Phase I - Solid Tumours, Multiple myeloma, Inflammation, Solid tumor; Phase II - Colorectal tumor, Melanoma, Non-small-cell lung Cancer, Pancreas tumor		Phase III; Phase II; Phase I		ASTRAZENECA PLC	5917187		1995	2015
5917204	AZD-1981	July 31, 2012					Phase II	Prostaglandin D2 receptor 2 antagonist	CCD	Phase II - Chronic obstructive pulmonary disease, Asthma		Phase II		ASTRAZENECA PLC	5917204		1995	2012
5916702	NCQ 616	7/4/1999					No Development	Dopamine receptor D2 antagonist	CCD	No Development - Psychotic disorders		No Development		ASTRAZENECA	5916702		1995	1999
5918066	AZD-5904	July 31, 2012					Discontinued	Myeloperoxidase inhibitor	CCD	Discontinued - Chronic obstructive pulmonary disease, Multiple sclerosis		Discontinued		ASTRAZENECA PLC	5918066		1995	2012
5918069	AZD4877	March 10, 2014		AZD4877 was discontinued from development due to insufficient clinical activity			Discontinued	Kinesin family member 11 inhibitor	CCD	Phase I - Neoplasm; Phase II - Bladder carcinoma; Discontinued - Solid tumor, Hematological carcinoma		Phase I; Phase II; Discontinued	JAN12_3	ASTRAZENECA PLC	5918069	MAR14_4	1995	2014
5918069	AZD4877	March 10, 2014		AZD4877 was discontinued from development due to insufficient clinical activity			Discontinued	Kinesin family member 11 inhibitor	CCD	Phase I - Neoplasm; Phase II - Bladder carcinoma; Discontinued - Solid tumor, Hematological carcinoma		Phase I; Phase II; Discontinued	JAN12_3	ASTRAZENECA PLC	5918069	JAN12_3	1995	2014
5917618	AZD-9684	December 26, 2013					Discontinued	Carboxypeptidase U inhibitor; Fibrinolysis stimulator	CCD	Discontinued - Thrombosis; Phase II - Pulmonary embolism		Discontinued; Phase II		ASTRAZENECA PLC	5917618		1995	2013
5918527	AZD-3783	May 17, 2012		In 2008 January 28, AstraZeneca had discontinued development of AZD-3783, an agent thought to have potential in the treatment of anxiety and depression			Discontinued	Antidepressant; Anxiolytic	CCD	Discontinued - Anxiety disorder, Depression; Phase I - Anxiety disorder, Major depressive disorder		Discontinued; Phase I		ASTRAZENECA PLC	5918527		1995	2012
5918177	AZD-4769	May 17, 2012					Discontinued	Antiproliferative	CCD	Discontinued - Dyslipidemia; Phase I - Lipid metabolism disorder; Preclinical - Lipid metabolism disorder		Discontinued; Phase I; Preclinical		ASTRAZENECA PLC	5918177		1995	2012
5918179	AZD-5672	May 17, 2012		AZD-5672 was discontinued in 2009 from clinical development due to lack of efficacy in rheumatoid arthritis			Discontinued	C-C chemokine receptor type 5 antagonist	CCD	Discontinued - Rheumatoid arthritis; Phase I - Rheumatoid arthritis		Discontinued; Phase I	JAN12_3	ASTRAZENECA PLC	5918179	JAN12_3	1995	2012
5915756	ARC 13950	11/29/2001					No Development	NMDA receptor antagonist	CCD	No Development - Epilepsy		No Development		ASTRAZENECA R&D CHARNWOOD	5915756		1995	2001
5915759	ZD 4054	February 09, 2015					Discontinued	Endothelin A receptor antagonist	CCD	Discontinued - PROSTATE CANCER; Phase III - PROSTATE CANCER; Phase II - INTERMITTENT CLAUDICATION, PERIPHERAL ARTERIAL DISEASE		Discontinued; Phase III; Phase II		ASTRAZENECA PLC	5915759	MAR14_4	1995	2015
5915759	ZD 4054	February 09, 2015					Discontinued	Endothelin A receptor antagonist	CCD	Discontinued - PROSTATE CANCER; Phase III - PROSTATE CANCER; Phase II - INTERMITTENT CLAUDICATION, PERIPHERAL ARTERIAL DISEASE		Discontinued; Phase III; Phase II		ASTRAZENECA PLC	5915759		1995	2015
5915760	ZD 4974	1/20/2006					No Development	Neurokinin 1 receptor antagonist; Neurokinin 2 receptor antagonist	CCD	No Development - Depression, Emesis, Inflammatory bowel disease, Pain, Anxiety disorders, Arthritis, Asthma, Micturition disorder, Cough, Major depressive disorder		No Development		ASTRAZENECA	5915760		1995	2006
5916170	BUCICLOVIR	9/1/2003					Preclinical	DNA synthesis inhibitor	CCD	Preclinical - Herpes simplex virus infection		Preclinical		ASTRAZENECA	5916170		1995	2003
5916339	AR-C89855	May 10, 2012					Discontinued	Dopamine receptor D1 agonist; Beta-2 adrenergic receptor agonist	CCD	Discontinued - Chronic obstructive pulmonary disease; Preclinical - Asthma, Chronic obstructive pulmonary disease		Discontinued; Preclinical		ASTRA ZENECA	5916339		1995	2012
5916517	CYC-103	2/15/2007					Preclinical	CDK inhibitor	CCD	Preclinical - Cancer; No Development - Cancer		Preclinical; Discontinued		ASTRAZENECA PLC	5916517		1995	2007
5916520	NU-6102	2/16/2007					Preclinical	CDK inhibitor	CCD	Preclinical - Cancer		Preclinical		ASTRAZENECA PLC	5916520		1995	2007
5917492	EXHERIN	August 14, 2015					No Development	Cadherin-2 antagonist; Angiogenesis inhibitor; Cell adhesion inhibitor	CCD	No Development - Cancer; Phase II - Cancer		No Development; Phase II		ASTRAZENECA PLC	5917492		1995	2015
5916559	AZD-1152	June 30, 2015					Discontinued	Aurora kinase B inhibitor	CCD	Discontinued - Solid tumors; Phase III - Solid tumors, Acute myeloid leukemia; Phase II - Diffuse large B-cell lymphoma		Discontinued; Phase III; Phase II		ASTRAZENECA PLC	5916559		1995	2015
5917362	AZD7545	9/30/2005					Discontinued	Pyruvate dehydrogenase kinase 2 inhibitor	CCD	Discontinued - Diabetes mellitus		Discontinued		ASTRAZENECA PLC	5917362		1995	2005
5918114	D-9421-C	June 09, 2014					Launched	Corticosteroid agonist	DD	Phase I - Crohns disease; Launched - Crohns disease		Phase I; Launched		ASTRAZENECA PLC	5918114		1995	2014
5917252	AZD2479	December 26, 2013		In April 2007 AstraZeneca terminated its 2005 licensing agreement with AVANIR for the development of AZD-2479. As a consequence, AstraZeneca discontinued further development of the compound.			Discontinued	Reverse cholesterol transport enhancer	CCD	Discontinued - Hyperlipidemia; Phase I - Dyslipidemia		Discontinued; Phase I		ASTRAZENECA PLC	5917252		1995	2013
5917402	AZD-6357	January 31, 2008					Discontinued	Anti-inflammatory	CCD	Discontinued - Osteoarthritis; Preclinical - Osteoarthritis		Discontinued; Preclinical		ASTRAZENECA PLC	5917402		1995	2008
5918135	AZD-8955	October 01, 2013					Discontinued	Matrix metalloproteinase inhibitor; Aggrecanase inhibitor	CCD	Discontinued - Osteoarthritis; No Development - Cancer; Phase II - Osteoarthritis; Preclinical - Cancer		Discontinued; No Development; Phase II; Preclinical		ASTRAZENECA PLC	5918135		1995	2013
5916762	GALNON	5/3/2005					Preclinical	Galanin receptor agonist	CCD	Preclinical - Epilepsy		Preclinical		ASTRAZENECA	5916762		1995	2005
5916773	ARC 63012 AR	7/4/1999					No Development	Dopamine receptor D1 agonist	CCD	No Development - Heart failure		No Development		ASTRAZENECA R&D CHARNWOOD	5916773		1995	1999
5916774	ARC 68164AA	6/6/2000					No Development	Beta-2 adrenergic receptor agonist; Dopamine receptor D2 agonist	CCD	No Development - Asthma, Chronic Obstructive Pulmonary Disease		No Development		ASTRAZENECA	5916774		1995	2000
5916775	ARC 68475AA	6/6/2000					No Development	Beta-2 adrenergic receptor agonist; Dopamine receptor D2 agonist	CCD	No Development - Asthma, Chronic Obstructive Pulmonary Disease		No Development		ASTRAZENECA	5916775		1995	2000
5916776	ARC 69457AA	6/6/2000					No Development	Beta-2 adrenergic receptor agonist; Dopamine receptor D2 agonist	CCD	No Development - Asthma, Chronic Obstructive Pulmonary Disease		No Development		ASTRAZENECA	5916776		1995	2000
5916946	LOMEGUATRIB	March 07, 2014		Astrazeneca discontinued the development of LOMEGUATRIB, due to factor involved in the resistance of tumors to methylating agents and nitrosureas.			Discontinued	O6-Alkylguanine-DNA alkyltransferase inhibitor	CCD	Phase II - Solid tumor, Metastatic melanoma, Colorectal carcinoma; Discontinued - Solid tumor, Metastatic melanoma		Phase II; Discontinued		ASTRAZENECA PLC	5916946		1995	2014
5916972	D 7193	5/27/2002					Discontinued	Cyclooxygenase inhibitor	CCD	Discontinued - Asthma		Discontinued		ASTRA MERCK INC	5916972		1995	2002
5916972	D 7193	5/27/2002					Discontinued	Cyclooxygenase inhibitor	CCD	Discontinued - Asthma		Discontinued		ASTRA AB	5916972		1995	2002
5917253	AZD3355	March 11, 2015		Development of compound for the treatment of gastroesophageal reflux disease has been discontinued due to failure of the compound to achieve a meaningful symptom benefit in phase IIb study.			Discontinued	GABAB receptor agonist	CCD	Phase II - GASTROESOPHAGEAL REFLUX DISEASE; Preclinical - CHRONIC COUGH; Discontinued - GASTROESOPHAGEAL REFLUX DISEASE		Discontinued; Phase II; Preclinical		ASTRAZENECA PLC	5917253		1995	2015
5917254	AZD2392	February 1, 2008					Discontinued	Anti-inflammatory	CCD	Discontinued - Asthma, Rhinitis; Preclinical - Asthma, Rhinitis		Discontinued; Preclinical		ASTRAZENECA PLC	5917254		1995	2008
5917255	AZD2207	January 1, 2011					Discontinued	Hypoglycemic	CCD	Phase 1 - Obesity, Diabetes mellitus; Discovery - Obesity, Diabetes mellitus; Discontinued - Obesity, Diabetes mellitus		Phase I; Discovery; Discontinued		ASTRAZENECA PLC	5917255		1995	2011
5917256	AZD1940	January 1, 2011		Discontinued due to CNS-retaled site effects			Discontinued	Analgesic	CCD	Discontinued - Pain; Preclinical - Pain		Discontinued; Preclinical		ASTRAZENECA PLC	5917256		1995	2011
5917277	AZD-0837	May 15, 2012		Discontinued due to Gastrointestinal disorders			Discontinued	Thrombin inhibitor; Coagulation inhibitor	CCD	Discontinued - Thrombosis; Phase II - Thrombosis; Phase I - Thrombosis		Discontinued; Phase II; Phase I		ASTRAZENECA PLC	5917277		1995	2012
5917278	AZD1080	June 11, 2009					Discontinued	Glycogen synthase kinase antagonist; Tau aggregation inhibitor	CCD	Discontinued - Alzheimer's disease; Phase 1 - Alzheimer's disease		Discontinued; Phase I		ASTRAZENECA PLC	5917278		1995	2009
5917279	AZD9272	March 16, 2009					Preclinical	Metabotropic glutamate receptor 1 antagonist; CNS modulator	CCD	Discovery - Neurological disease; Phase 1 - Neuropathic pain, Neurological disease; Discontinued - Gastroesophageal reflux, Neurological disease, Neuropathic pain		Discovery; Phase I; Discontinued		ASTRAZENECA PLC	5917279		1995	2009
5917280	AZD7009	2/8/2007					Discontinued	Potassium channel blocker	CCD	Discontinued - Atrial fibrillation		Discontinued		ASTRAZENECA PLC	5917280		1995	2007
5917281	AZD1092	6/21/2006					Discontinued	Hypoglycemic	CCD	Discontinued - Diabetes mellitus		Discontinued		ASTRAZENECA PLC	5917281		1995	2006
5917282	AZD1175	September 1, 2009					Discontinued	Hypoglycemic	CCD	Discontinued - Diabetes mellitus, Obesity; Phase 1 - Diabetes mellitus, Obesity		Discontinued; Phase I		ASTRAZENECA PLC	5917282		1995	2009
5917401	AZD-3778	January 1, 2011		Failure to meet their target profiles			Discontinued	CC-chemokine receptor-3 antagonist; Histamine H1 receptor antagonist	CCD	Phase 2 - Rhinitis; Phase 1 - Asthma, Rhinitis; Discontinued - Asthma, Rhinitis		Phase II; Phase I; Discontinued		ASTRAZENECA PLC	5917401		1995	2011
5917403	AZD-3342	December 26, 2013		AstraZeneca discontinued the development of AZD-3342 for the treatment of chronic obstructive pulmonary disease as a result of its failure to meet its target product profiles.			Discontinued	Proteinase inhibitor	CCD	Discontinued - Chronic obstructive pulmonary disease; Phase I - Chronic obstructive pulmonary disease		Discontinued; Phase I		ASTRAZENECA PLC	5917403		1995	2013
5917404	AZD-8309	January 1, 2011		Discontinued as a result of its failure to meet its target product profiles			Discontinued	Chemokine receptor antagonist	CCD	Phase 1 - Chronic Obstructive Pulmonary Disease, Rheumatoid arthritis; Discovery - Chronic Obstructive Pulmonary Disease, Rheumatoid arthritis; Discontinued - Chronic Obstructive Pulmonary Disease, Rheumatoid arthritis		Phase I; Discovery; Discontinued		ASTRAZENECA PLC	5917404		1995	2011
5917405	AZD-9056	July 31, 2012		Discontinued the development of AZD9056 for the treatment of rheumatoid arthritis due to lack of efficacy			Discontinued	P2X7 purinoceptor antagonist	CCD	Discontinued - Osteoarthritis, Chronic obstructive pulmonary disease, Inflammatory bowel disease, Rheumatoid arthritis		Discontinued		ASTRAZENECA PLC	5917405		1995	2012
5918277	DAPAGLIFLOZIN	January 17, 2014	PRESCRIPTION DRUG			Single oral dose of 10 mg per day	Launched	Sodium/glucose cotransporter 2 inhibitor	DD	Launched - Diabetes mellitus Type 2	November 12, 2012	Launched		ASTRAZENECA PLC	5918277		2012	2014
5918287	AZD-6370	May 17, 2012					Discontinued	Glucokinase activator	CCD	Discontinued - Non-insulin dependent diabetes mellitus; Preclinical - Diabetes mellitus		Discontinued; Preclinical		ASTRAZENECA PLC	5918287		1995	2012
5918811	AZD8931	June 05, 2014					Phase II	EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITOR; ERBB2 INHIBITOR; ERBB3 INHIBITOR	CCD	Phase II - Non-small cell lung cancer; Discontinued - Metastatic breast cancer		Phase II; Discontinued		ASTRAZENECA PLC	5918811		1995	2014
5918813	AZD1845	9/25/2007					Preclinical	Anticancer	CCD	Preclinical - Solid tumor		Preclinical		ASTRAZENECA PLC	5918813		1995	2007
5918814	AZD8330	June 04, 2014		Development of the compound has been discontinued due to safety and efficacy concerns			Discontinued	MEK1/2 kinase inhibitor	CCD	Discontinued - Solid tumor; Phase I - Solid tumor		Discontinued; Phase I		ASTRAZENECA PLC	5918814		1995	2014
5918815	AZD3646	May 17, 2012		In 2007 October 8, AstraZeneca had discontinued development of AZD-3646			Discontinued	Anticancer	CCD	Discontinued - Hematological malignancies, Solid tumor; Preclinical - Cancer		Discontinued; Preclinical		ASTRAZENECA PLC	5918815		1995	2012
5918816	AZD1305	May 15, 2012					Discontinued	L-type Calcium channel, Sodiun channel, Potassium channel blocker	CCD	Discontinued - Atrial fibrillation; Phase I - Heart arrhythmia; Preclinical - Heart arrhythmia		Discontinued; Phase I; Preclinical	JAN12_3	ASTRAZENECA PLC	5918816	JAN12_3	1995	2012
5918817	AZD4121	May 06, 2014					Discontinued	Cholesterol absorption inhibitor	CCD	Phase II - DYSLIPIDEMIA; Discontinued - DYSLIPIDEMIA		Phase II; Discontinued		ASTRAZENECA PLC.	5918817	MAY14_5	1995	2014
5918817	AZD4121	May 06, 2014					Discontinued	Cholesterol absorption inhibitor	CCD	Phase II - DYSLIPIDEMIA; Discontinued - DYSLIPIDEMIA		Phase II; Discontinued		ASTRAZENECA PLC	5918817		1995	2014
5918818	AZD8081	8/13/2007					Discontinued	Gastrointestinal system agent	CCD	Discontinued - Functional bowel disorder; Preclinical - Functional bowel disorder		Discontinued; Preclinical	JAN12_3	ASTRAZENECA PLC	5918818	JAN12_3	1995	2007
5918819	AZD9335	8/13/2007					Discontinued	Gastrointestinal system agent; Analgesic	CCD	Discontinued - Gastroesophageal reflux, Neuropathic pain; Preclinical - Gastroesophageal reflux, Neuropathic pain		Discontinued; Preclinical		ASTRAZENECA PLC	5918819		1995	2007
5918820	AZD6538	8/13/2007					Discontinued	Analgesic	CCD	Discontinued - Gastroesophageal reflux, Neuropathic pain; Preclinical - Gastroesophageal reflux, Neuropathic pain		Discontinued; Preclinical		ASTRAZENECA PLC	5918820		1995	2007
5918821	AZD6605	May 17, 2012					Discontinued	Anti-inflammatory	CCD	Discontinued - Osteoarthritis; Preclinical - Osteoarthritis		Discontinued; Preclinical		ASTRAZENECA PLC	5918821		1995	2012
5919363	AZD-5099	June 11, 2014		Development of compound has been discontinued due to the lack of safety and efficacy			Discontinued	DNA gyrase inhibitor	CCD	Discontinued - Infectious disease; Phase I - Infectious disease		Discontinued; Phase I		ASTRAZENECA PLC	5919363		1995	2014
5919364	AZD-5329	4/13/2007					Preclinical		CCD	Preclinical - Functional gastrointestinal disease		Preclinical		ASTRAZENECA PLC	5919364		1995	2007
5919365	AZD-5861	4/12/2007					Preclinical	Lipid metabolism modulator	CCD	Preclinical - Dyslipidaemia		Preclinical		ASTRAZENECA PLC	5919365		1995	2007
5919366	AZD-6280	May 17, 2012					Discontinued	Anxiolytic	CCD	Discontinued - Anxiety disorder; Preclinical - Anxiety		Discontinued; Preclinical	JAN12_3	ASTRAZENECA PLC	5919366	JAN12_3	1995	2012
5918822	AZD9343	April 13, 2007		By June 2006, the drug's development had been discontinued			Discontinued	GABA(B) receptor agonist	CCD	Phase 1 - Gastro esophageal reflux disease; Preclinical - Gastro esophageal reflux disease; Discontinued - Gastro esophageal reflux disease		Phase I; Preclinical; Discontinued	JAN12_3	ASTRAZENECA PLC	5918822	JAN12_3	1995	2007
5918823	AZD2914	4/23/2007		Withdrawn due to risk of teratogenicity			Discontinued	Anti-inflammatory	CCD	Discontinued - Chronic obstructive pulmonary disease; Preclinical - Chronic obstructive pulmonary disease		Discontinued; Preclinical		ASTRAZENECA PLC	5918823		1995	2007
5918824	AZD1236	July 31, 2012					Discontinued	Matrix metalloproteinase 9 inhibitor; Matrix metalloproteinase 12 inhibitor	CCD	Discontinued - Chronic obstructive pulmonary disease, Cystic fibrosis		Discontinued		ASTRAZENECA PLC	5918824		1995	2012
5918825	AZD4818	May 17, 2012		AZD-4818 was discontinued in 2008 for the treatment of COPD following the outcome of clinical efficacy studies that failed to support further investment.			Discontinued	C-C chemokine receptor type 1 antagonist	CCD	Discontinued - Chronic obstructive pulmonary disease; Phase I - Chronic obstructive pulmonary disease; Preclinical - Chronic obstructive pulmonary disease		Discontinued; Phase I; Preclinical	JAN12_3	ASTRAZENECA PLC	5918825	JAN12_3	1995	2012
5919539	KU-60019	April 16, 2007					Preclinical	Ataxia telangiectasia mutated inhibitor	CCD	Preclinical - Cancer, Retrovirus infection		Preclinical	JAN12_3	ASTRAZENECA PLC	5919539	JAN12_3	1995	2007
5920480	AXC-3742	July 17, 2002					No Development	Opioid modulator	CCD	No Development - Pain; Preclinical - Pain		No Development; Preclinical	JUN10	ASTRA AB; ALANEX	5920480	JUN10	1995	2002
5919367	AZD-6918	January 1, 2011					Discontinued	Antitumour	CCD	Discontinued - Solid tumor; Phase I - Solid tumor; Preclinical - Solid tumor		Phase I		ASTRAZENECA PLC	5919367		1995	2011
5919368	AZD-7903	2/13/2007					Preclinical	Analgesic	CCD	Preclinical - Analgesia		Preclinical		ASTRAZENECA PLC	5919368		1995	2007
5919369	AZD-8075	February 23, 2009					Discontinued	Anti-inflammatory	CCD	Discontinued - Asthma, Chronic obstructive pulmonary disease; Phase I - Asthma, Chronic obstructive pulmonary disease		Discontinued; Phase I		ASTRAZENECA PLC	5919369		1995	2009
5919370	AZD-8848	September 18, 2015		Due to lack of safety/Efficacy results.			Discontinued	Toll-like receptor 7 agonist	CCD	Discontinued - Asthma; Phase II - Bronchial asthma, Allergic rhinitis; Phase I - Butyrylcholinesterase deficiency		Discontinued; Phase II; Phase I	JAN12_3	ASTRAZENECA PLC	5919370	JAN12_3	1995	2015
5919371	AZD-9468	4/20/2007					Preclinical	Antitumor	CCD	Preclinical - Solid tumours		Preclinical		ASTRAZENECA PLC	5919371		1995	2007
5920058	AZD-6213	8/7/2009					No Development	Anti-inflammatory	CCD	Preclinical - Chronic obstructive pulmonary disease; No Development - Chronic obstructive pulmonary disease		Preclinical; No Development	JAN10	ASTRAZENECA PLC.	5920058	JAN10	1995	2009
5920059	AZD-6302	8/7/2009					No Development	Antibacterial	CCD	Preclinical - MRSA infection; No Development - MRSA infection		Preclinical; No Development	JAN10	ASTRAZENECA PLC.	5920059	JAN10	1995	2009
5920060	AZD-7420	8/7/2009					No Development	Anti-inflammatory	CCD	Preclinical - Chronic obstructive pulmonary disease; No Development - Chronic obstructive pulmonary disease		Preclinical; No Development	JAN10	ASTRAZENECA PLC	5920060	JAN10	1995	2009
5920367	AZD-8329	March 12, 2014		Development of compound was discontinued due to lack of safety and efficacy			Discontinued	11-Beta hydroxysteroid dehydrogenase inhibitor	CCD	Phase I - Obesity, Type-2 diabetes; Discontinued - Diabetes		Phase I; Discontinued	MAR10	ASTRAZENECA PLC	5920367	MAR14_4	1995	2014
5920368	AZD-8418	March 13, 2014					Discontinued	Glutamatergic modulator	CCD	Phase I - Schizophrenia; Discontinued - Schizophrenia		Phase I; Discontinued	MAR10	ASTRAZENECA PLC	5920368	MAR14_4	1995	2014
5920369	AZD-9742	March 13, 2014		Development of AZD-9742 was discontinued due to lack of safety and efficacy.			Discontinued	Antibacterial	CCD	Phase I - Methicillin-resistant staphylococcus aureus infection; Discontinued - Methicillin-resistant staphylococcus aureus infection		Phase I; Discontinued	MAR10	ASTRAZENECA PLC	5920369	MAR14_4	1995	2014
5918316	D-3800	6/19/2007					Discontinued	Appetite suppressant; Antiobesity	CCD	Discontinued - Obesity		Discontinued		ASTRA AB	5918316		1995	2007
5919204	AZD-5069	March 28, 2016					Phase II	CXCR2 CHEMOKINE RECEPTOR ANTAGONIST	CCD	Phase II - ASTHMA, BRONCHIECTASIS, CHRONIC OBSTRUCTIVE PULMONARY DISEASE		Phase II		ASTRAZENECA PLC	5919204	APR16	1995	2016
5919204	AZD-5069	March 28, 2016					Phase II	CXCR2 CHEMOKINE RECEPTOR ANTAGONIST	CCD	Phase II - ASTHMA, BRONCHIECTASIS, CHRONIC OBSTRUCTIVE PULMONARY DISEASE		Phase II		ASTRAZENECA PLC	5919204		1995	2016
5918826	AZD9668	May 22, 2014					Discontinued	Neutrophil elastase inhibitor	CCD	Discontinued - Chronic obstructive pulmonary disease; Phase II - Chronic obstructive pulmonary disease, Cystic Fibrosis		Discontinued; Phase II	JAN12_3	ASTRAZENECA PLC	5918826	JAN12_3	1995	2014
5918827	AZD9215	8/13/2007		Withdrawn due to toxicity problems when used to irrigate wounds and ineffective for the treatment of urinary tract infections			Discontinued	Anti-inflammatory	CCD	Discontinued - Asthma; Preclinical - Asthma		Discontinued; Preclinical		ASTRAZENECA PLC	5918827		1995	2007
5918828	AZD1678	8/13/2007		Withdrawn due to toxicity problems when used to irrigate wounds and ineffective for the treatment of urinary tract infections			Discontinued	Anti-inflammatory	CCD	Discontinued - Asthma; Preclinical - Asthma		Discontinued; Preclinical		ASTRAZENECA PLC	5918828		1995	2007
5919013	A-831	9/7/2007					Phase II	RNA polymerase inhibitor; HCV NS5a inhibitor	CCD	Phase II - Hepatitis C virus infection; Discontinued - Hepatitis C virus infection		Phase II; Discontinued		ASTRAZENECA PLC.	5919013		1995	2007
5919013	A-831	9/7/2007					Phase II	RNA polymerase inhibitor; HCV NS5a inhibitor	CCD	Phase II - Hepatitis C virus infection; Discontinued - Hepatitis C virus infection		Phase II; Discontinued		ASTRAZENECA PLC	5919013		1995	2007
5919380	AZ-12304146	4/12/2007					Preclinical	Beta-site APP-cleaving enzyme inhibitor; Beta-amyloid synthesis inhibitor	CCD	Preclinical - Alzheimer's disease		Preclinical		ASTRAZENECA PLC	5919380		1995	2007
5919047	FG-4592	February 12, 2014					Phase III	Hypoxia-inducible factor prolyl hydroxylase inhibitor	CCD	Phase III - ANEMIA IN CHRONIC KIDNEY DISEASE		Phase III	JAN12_3	ASTRAZENECA PLC	5919047	JAN12_3	1995	2014
5922949	LAS-333	May 24, 2002					No Development	Analgesic	CCD	No Development - Pain		No Development	DEC10	AstraZeneca Canada Inc. (AstraZeneca plc)	5922949	DEC10	1995	2002
5919953	AZD-3409	3/30/2009					Discontinued	Farnesyltransferase inhibitor	CCD	Phase I - Solid tumor; Preclinical - Solid tumor; Discontinued - Solid tumor		Preclinical; Phase I; Discontinued	JAN10	ASTRAZENECA PLC.	5919953	JAN10	1995	2009
5920704	(S)-(-)-AR-A 008055	December 6, 2005					No Development	GABA A receptor agonist	CCD	No Development - Neurotoxicity drug-induced, Neurodegenerative disease; Preclinical - Neurotoxicity drug-induced, Neurodegenerative disease		No Development; Preclinical	JUN10	ASTRAZENECA PLC.	5920704	JUN10	1995	2005
5918350	AZD-1656	July 15, 2015					Discontinued	Glucokinase activator	CCD	Discontinued - Type 2 diabetes mellitus; Phase II - Type 2 diabetes mellitus; Preclinical - Obesity		Discontinued; Phase II; Preclinical		ASTRAZENECA PLC	5918350		1995	2015
5918351	AZD-3988	May 17, 2012		In January 28, 2008  AstraZeneca is no longer developing AZD-3988 for the treatment of obesity and diabetes			Discontinued	Hypoglycemic	CCD	Discontinued - Metabolic disorders; Preclinical - Obesity, Diabetes mellitus		Discontinued; Preclinical		ASTRAZENECA PLC	5918351		1995	2012
5917927	KU-59652	4/21/2006					Preclinical	ATM Kinase Inhibitor; Serine-threonine kinase receptor inhibitor	CCD	Preclinical - Cancer, Retrovirus infection		Preclinical		ASTRAZENECA PLC	5917927		1995	2006
5915954	CB-3717	9/1/2003					Phase II	Thymidylate synthase inhibitor	CCD	Phase II - Colorectal cancer		Phase II		ASTRAZENECA	5915954		1995	2003
5918877	AZD6067	9/25/2007					Preclinical	Protease inhibitor	CCD	Preclinical - Chronic obstructive pulmonary disease		Preclinical		ASTRAZENECA PLC	5918877		1995	2007
5918878	AZD7928	8/13/2007					Discontinued	Anti-inflammatory	CCD	Discontinued - Chronic obstructive pulmonary disease; Preclinical - Chronic obstructive pulmonary disease		Discontinued; Preclinical		ASTRAZENECA PLC	5918878		1995	2007
5918879	AZD1744	April 24, 2014					Phase I	C-C CHEMOKINE RECEPTOR 3 ANTAGONIST; HISTAMINE H1 RECEPTOR ANTAGONIST	CCD	Phase I - ASTHMA, CHRONIC OBSTRUCTIVE PULMONARY DISEASE; Preclinical - ASTHMA, RHINITIS		Phase I; Preclinical		ASTRAZENECA PLC	5918879		1995	2014
5918880	AZD3825	9/25/2007					Preclinical	Anti-inflammatory	CCD	Preclinical - Asthma		Preclinical		ASTRAZENECA PLC	5918880		1995	2007
5918890	AZD3241	June 04, 2014					Phase II	Myeloperoxidase inhibitor	CCD	Phase II - Parkinson's disease		Phase II		ASTRAZENECA PLC	5918890		1995	2014
5918891	AZD7512	9/8/2006					Preclinical		CCD	Preclinical - Anxiety disorder, Major depressive disorder		Preclinical		ASTRAZENECA PLC	5918891		1995	2006
5918892	AZD9935	6/21/2006					Preclinical	VEGF antagonist; EGFR family tyrosine kinase receptor inhibitor; Angiogenesis inhibitor	CCD	Preclinical - Solid tumor		Preclinical		ASTRAZENECA PLC	5918892		1995	2006
5918893	AZD-8797	2/13/2007					Preclinical	CNS modulator	CCD	Preclinical - Multiple sclerosis		Preclinical		ASTRAZENECA PLC	5918893		1995	2007
5918895	AZD-8450	6/21/2006					Preclinical	Lipid metabolism modulator	CCD	Preclinical - Lipid metabolism disorder		Preclinical		ASTRAZENECA PLC	5918895		1995	2006
5918896	AZD-8593	6/21/2006					Preclinical	Blood clotting modulator	CCD	Preclinical - Bleeding		Preclinical		ASTRAZENECA PLC	5918896		1995	2006
5919612	AZD-1283	May 15, 2012					Discontinued	Coagulation inhibitor	CCD	Discontinued - Thrombosis		Discontinued		ASTRAZENECA PLC	5919612		1995	2012
5919613	AZD-1386	May 15, 2012					Discontinued	Analgesic	CCD	Discontinued - Gastroesophageal reflux disease, Neuropathic pain; Preclinical - Pain		Discontinued; Preclinical		ASTRAZENECA PLC	5919613		1995	2012
5919614	AZD-2066	May 15, 2012					Discontinued	Analgesic	CCD	Discontinued - Major depressive disorder, Neuropathic pain, Gastroesophageal reflux disease; Preclinical - Gastroesophageal reflux disease, Pain		Discontinued; Preclinical		ASTRAZENECA PLC	5919614		1995	2012
5919615	AZD-2624	May 17, 2012		AZD-2624 was discontinued in 2009 as it did not support the hypothesis that NK3 receptor antagonists have antipsychotic effects in schizophrenia			Discontinued	Neurokinin-3 receptor antagonist	CCD	Discontinued - Schizophrenia; Preclinical - Schizophrenia		Discontinued; Preclinical	JAN12_3	ASTRAZENECA PLC	5919615	JAN12_3	1995	2012
5919616	AZD-2932	4/20/2007					Preclinical	Anticancer	CCD	Preclinical - Solid tumor		Preclinical		ASTRAZENECA PLC	5919616		1995	2007
5919617	AZD-3199	May 17, 2012		AstraZeneca plc. discontinued development of projects between 27 January 2011 and 31 December 2011 due to Economic/Regulatory reason			Discontinued	Beta-2 adrenergic receptor agonist	CCD	Discontinued - Asthma, Chronic obstructive pulmonary disease; Phase II - Asthma, Chronic obstructive pulmonary disease; Phase I - Asthma, Chronic obstructive pulmonary disease; Preclinical - Inflammatory disorders		Discontinued; Phase II; Phase I; Preclinical		ASTRAZENECA PLC	5919617		1995	2012
5919618	AZD-4992	May 17, 2012					Discontinued	Estrogen receptor antagonist	CCD	Discontinued - Breast cancer; Preclinical - Cancer		Discontinued; Preclinical		ASTRAZENECA PLC	5919618		1995	2012
5919619	AZD-0328	July 31, 2012					Discontinued	Alpha-7 neuronal nicotinic acetylcholine receptor agonist	CCD	Discontinued - Schizophrenia, Alzheimer's disease		Discontinued		ASTRAZENECA PLC	5919619		1995	2012
5919620	ASTRA II	7/1/2003					Preclinical	Nicotinic acetylcholine receptor alpha7 agonist	CCD	Preclinical - Cognitive disorder, Alzheimer's disease		Preclinical		ASTRAZENECA PLC	5919620		1995	2003
5919621	AR-R-234655	9/1/2001					Preclinical	Nicotinic acetylcholine receptor alpha7 agonist	CCD	Preclinical - Cognitive disorder		Preclinical		ASTRAZENECA PLC	5919621		1995	2001
5919687	AZD-6765	July 15, 2015		Drug failed for both safety and efficacy			Discontinued	Antidepressant	CCD	Discontinued - Major depressive disorder; Phase II - Depression; Phase I - Depression		Discontinued; Phase II; Phase I		ASTRAZENECA	5919687		1995	2015
5920034	AZ-10397767	8/11/2009					No Development	CCR2 chemokine receptor Antagonist; CXCR2 chemokine receptor Antagonist	CCD	Preclinical - Rheumatoid arthritis; No Development - Rheumatoid arthritis		Preclinical; No Development	JAN10	ASTRAZENECA PLC	5920034	JAN10	1995	2009
5920038	AR-H049020	3/24/2004					Discontinued	Insulin Sensitizer; Peroxisome proliferator activated receptor Agonist	CCD	Phase I - Non-insulin dependent diabetes; Discontinued - Non-insulin dependent diabetes		Phase I; Discontinued	JAN10	ASTRAZENECA PLC	5920038	JAN10	1995	2004
5920169	TC-5214	August 14, 2015		The results were not compelling enough to justify the compounds continued development in overactive bladder			Discontinued	Nicotinic acetylcholine receptor alpha4beta2 antagonist	CCD	Discontinued - Major depressive disorder, Overactive bladder syndrome; Phase III - Major depressive disorder; Phase II - Refractory hypertension, Overactive bladder syndrome; Phase I - Chronic hypertension		Discontinued; Phase III; Phase II; Phase I	MAR10	ASTRAZENECA PLC.	5920169	MAR14_4	1995	2015
5920312	AZD-4017	June 30, 2015		Development of the drug is discontinued due to lack of safety and efficacy			Discontinued	11-Beta hydroxysteroid dehydrogenase inhibitor	CCD	Discontinued - Obesity, Type 2 diabetes mellitus; Phase II - Glaucoma, Idiopathic intracranial hypertension, Ocular hypertension		Discontinued; Phase II	MAR10	ASTRAZENECA PLC.	5920312	MAR14_4	1995	2015
5920315	AZD-5423	June 30, 2015					Discontinued	Glucocorticoid receptor agonist	CCD	Discontinued - Asthma, Chronic obstructive pulmonary disease; Phase II - Asthma, Chronic obstructive pulmonary disease		Discontinued; Phase II	MAR10	ASTRAZENECA	5920315	MAR14_4	1995	2015
5920446	AR-A-008055	December 16, 2005					No Development	GABA A receptor agonist; CNS modulator	CCD	Preclinical - Neurodegenerative disease, Neurotoxicity drug-induced; No Development - Neurodegenerative disease, Neurotoxicity drug-induced		Preclinical; No Development	JUN10	ASTRAZENECA PLC.	5920446	JUN10	1995	2005
5920448	AR-C73346XX	May 27, 2002					No Development	Phospholipase A2 inhibitor	CCD	Preclinical - Inflammatory disease; No Development - Inflammatory disease		Preclinical	JUN10	ASTRA R&D CHARNWOOD (ASTRAZENECA PLC.)	5920448	JUN10	1995	2002
5920449	AR-M100150	May 30, 2002					No Development	Opioid receptor delta antagonist	CCD	No Development - Pain; Preclinical - Pain		No Development; Preclinical	JUN10	ASTRAZENECA PLC	5920449	JUN10	1995	2002
5920971	AZD-1446	February 12, 2010					Phase II	Nicotinic acetylcholine receptor alpha4beta2 modulator	CCD	Phase 2 - Alzheimer's disease; Phase 1 - Cognitive disorder; Discovery - Cognitive disorder		Phase 2; Phase 1; Discovery	JUN10	ASTRAZENECA PLC.; TARGACEPT INC	5920971	JUN10	1995	2010
5920972	AZD-1480	September 25, 2013		AstraZeneca decided to stop the internal and external clinical development of AZD1480. This decision was made after a full review of data from all the studies of AZD1480 and an assessment of the current benefit-risk profile, with a particular focus on neurologic adverse events (AEs) and pharmacodynamics (PD) data at the various doses in the Phase I programme. Enrolment to all AZD1480 clinical studies was closed.			Discontinued	AZD-1480 blocks cell proliferation and induces apoptosis of myeloma cell lines by concomitant inhibition of phosphorylation of JAK2, STAT3 and MAPK signaling proteins.	CCD	Discontinued - Primary myelofibrosis, Post-polycythaemia vera, Essential thrombocythaemia myelofibrosis; Phase I - Primary myelofibrosis, Post-polycythaemia vera, Essential thrombocythaemia myelofibrosis		Discontinued; Phase I	JUN10	ASTRAZENECA PLC.	5920972	JUN10	1995	2013
5920973	AZD-7268	July 31, 2012					Discontinued	Enkephalinergic receptor modulator	CCD	Discontinued - Anxiety, Depression		Discontinued	JUN10	ASTRAZENECA PLC.	5920973	JUN10	1995	2012
5920974	AZD-9164	September 26, 2013					Discontinued	Muscarinic receptor antagonist	CCD	Discontinued - Chronic obstructive pulmonary disease; Phase II - Chronic obstructive pulmonary disease		Discontinued; Phase II	JUN10	ASTRAZENECA PLC.	5920974	JUN10	1995	2013
5921876	AZD-6553	March 12, 2014					Discontinued	Protease inhibitor	CCD	Discontinued - Chronic obstructive pulmonary disease; Phase I - Chronic obstructive pulmonary disease; Preclinical - Chronic obstructive pulmonary disease		Discontinued; Phase I; Preclinical	SEP10	ASTRAZENECA PLC.	5921876	SEP10	1995	2014
5921877	AZD-8683	February 14, 2014		Development of drug was discontinued due to lack of safety and efficacy			Discontinued	Muscarinic M3 receptor antagonist	CCD	Phase II - CHRONIC OBSTRUCTIVE PULMONARY DISEASE; Discontinued - CHRONIC OBSTRUCTIVE PULMONARY DISEASE		Phase II; Discontinued	SEP10	ASTRAZENECA PLC.	5921877	SEP10	1995	2014
5921877	AZD-8683	February 14, 2014		Development of drug was discontinued due to lack of safety and efficacy			Discontinued	Muscarinic M3 receptor antagonist	CCD	Phase II - CHRONIC OBSTRUCTIVE PULMONARY DISEASE; Discontinued - CHRONIC OBSTRUCTIVE PULMONARY DISEASE		Phase II; Discontinued	SEP10	ASTRAZENECA PLC.; QUINTILES TRANSNATIONAL CORP	5921877	SEP10	1995	2014
5921878	AZM-1	November 02,2009					Preclinical	Muscarinic M1 receptor agonist	CCD	Preclinical - Neuropathic pain		Preclinical	SEP10	ASTRAZENECA PLC.	5921878	SEP10	1995	2009
5922208	olaparib	December 22, 2014	PRESCRIPTION DRUG			Recommended dose is 400 mg taken twice daily	Launched	Poly [Adp-Ribose] Polymerase inhibitor	DD	Launched - ADVANCED OVARIAN CANCER	December 19, 2014	Launched	DEC10	ASTRAZENECA	5922208	JAN15	2014	2014
5922208	olaparib	December 22, 2014	PRESCRIPTION DRUG			Recommended dose is 400 mg taken twice daily	Launched	Poly [Adp-Ribose] Polymerase inhibitor	DD	Launched - ADVANCED OVARIAN CANCER	December 19, 2014	Launched	DEC10	AstraZeneca plc.; Cancer Research Campaign Technology Ltd.; The University of Newcastle Upon Tyne; KuDOS Pharmaceuticals Ltd.	5922208	DEC10	2014	2014
5921319	D-7003	September 13,2001					No Development	Mucolytic agent	CCD	No Development - Respiratory congestion, Cough; Phase 3 - Respiratory congestion, Cough		No Development; Phase III	SEP10	ASTRA DRACO AB	5921319	SEP10	1995	2001
5922056	AZ-23	January 15, 2010					Preclinical	Trk tyrosine kinase inhibitor; Anticancer	CCD	Preclinical - Cancer		Preclinical	DEC10	AstraZeneca plc.	5922056	DEC10	1995	2010
5922057	AZ-301	April 15, 2009					Preclinical	11-Beta hydroxysteroid dehydrogenase 1 inhibitor	CCD	Preclinical - Obesity		Preclinical	DEC10	AstraZeneca plc.	5922057	DEC10	1995	2009
5922221	ZD-4007	May 29, 2002					No Development	5-lipoxygenase inhibitor	CCD	No Development - Chronic obstructive pulmonary disease; Preclinical - Chronic obstructive pulmonary disease		No Development; Preclinical	DEC10	AstraZeneca plc.	5922221	DEC10	1995	2002
5922222	ZD-4794	November 30, 2005					No Development	Tachykinin receptor 1 antagonist	CCD	No Development - Major depressive disorder; Preclinical - Major depressive disorder		No Development; Preclinical	DEC10	AstraZeneca plc.	5922222	DEC10	1995	2005
5922806	AZD-2014	February 05, 2014					Phase II	mTOR inhibitor	CCD	Phase I - METASTATIC BREAST CANCER; Phase II - SOLID TUMOR, RENAL CARCINOMA		Phase I; Phase II	DEC10	ASTRAZENECA PLC.	5922806	DEC10	1995	2014
5922806	AZD-2014	February 05, 2014					Phase II	mTOR inhibitor	CCD	Phase I - METASTATIC BREAST CANCER; Phase II - SOLID TUMOR, RENAL CARCINOMA		Phase I; Phase II	DEC10	AstraZeneca; KuDOS Pharmaceuticals Ltd.	5922806	DEC10	1995	2014
5921757	AR-C117977	November 17,2008					Preclinical	Monocarboxylate transporter-1 inhibitor	CCD	Preclinical - Transplant rejection		Preclinical	SEP10	ASTRAZENECA PLC.	5921757	SEP10	1995	2008
5921782	CM-101	May 12,2009					No Development	Angiogenesis inhibitor	CCD	Phase 2 - Solid tumor; Phase 1 - Cancer; No Development - Cancer, Nervous system injury, Reperfusion injury, Rheumatoid arthritis, Wound healing, Solid tumor, Spinal cord tumor; Discontinued - Solid tumor; Discovery - Nervous system injury, Reperfusion injury, Rheumatoid arthritis, Wound healing, Solid tumor, Spinal cord tumor		Phase II; Phase I; No Development; Discontinued	SEP10	ASTRAZENECA PLC	5921782	SEP10	1995	2009
5921069	ICI-245991	March 14, 2014					Suspended	Bile acid sequestrant; Antihyperlipidemic	CCD	Suspended - Atherosclerosis, Hyperlipidemia; Preclinical - Hyperlipidemia		Suspended; Preclinical	JUN10	ASTRAZENECA PLC	5921069	JUN10	1995	2014
5921636	ICI-211965	March 14, 2014					Suspended	5-Lipoxygenase inhibitor	CCD	Suspended - Inflammatory diseases; Preclinical - Inflammatory disease		Suspended; Preclinical	SEP10	ASTRAZENECA PLC	5921636	SEP10	1995	2014
5922541	AZ-11657312	May 13, 2009					Preclinical	P2X7 purinoceptor antagonist	CCD	Preclinical - Arthritis		Preclinical	DEC10	AstraZeneca plc.	5922541	DEC10	1995	2009
5923123	H-29030	March 13, 2014					No Development	Lipid peroxidation inhibitor	CCD	No Development - Atherosclerosis; Preclinical - Atherosclerosis		No Development; Preclinical	APR11_2	Astra Hassle AB (AstraZeneca plc)	5923123	APR11_2	1995	2014
5921836	AR-M103180	September 18,2008					Preclinical	Cannabinoid CB2 receptor agonist	CCD	Preclinical - Pain		Preclinical	SEP10	ASTRAZENECA PLC.	5921836	SEP10	1995	2008
5922154	AZD-2743	March 23, 2010					No Development	Anti-inflammatory; Respiratory system agent	CCD	No Development - Chronic obstructive pulmonary disease; Preclinical - Chronic obstructive pulmonary disease		No Development; Preclinical	DEC10	AstraZeneca plc.	5922154	DEC10	1995	2010
5922730	FPL-15609	July 17, 2002					No Development	NMDA receptor antagonist	CCD	No Development - Pain; Preclinical - Pain		No Development; Preclinical	DEC10	Astra AB (AstraZeneca plc.)	5922730	DEC10	1995	2002
5922732	FPL-67047XX	March 13, 2014					No Development	Phospholipase A2 inhibitor	CCD	No Development - Inflammatory disease; Preclinical - Inflammatory disease		No Development; Preclinical	DEC10	Astra Ltd. (AstraZeneca plc.)	5922732	DEC10	1995	2014
5923775	EBP921	June 04, 2014					Phase II	FARNESYL TRANSFERASE INHIBITOR; PRENYLATION INHIBITOR; GERANYLGERANYLTRANSFERASE INHIBITOR	CCD	Phase I - SOLID TUMOR; Phase II - HEPATITIS D VIRUS INFECTION; Discontinued - SOLID TUMOR		Discontinued; Phase II; Phase I	OCT11_4	ASTRAZENECA PLC	5923775	JUN14_4	1995	2014
5924465	ZD-4927	March 12, 2014					Discontinued	Coagulation factor Xa inhibitor	CCD	Discontinued - Coagulation		Discontinued	JAN12_3	AstraZeneca	5924465	JAN12_3	1995	2014
5924466	Ticagrelor	July 13, 2012	PRESCRIPTION DRUG			Initiate BRILINTA treatment with a 180 mg (two 90 mg tablets) loading dose and continue treatment with 90 mg twice daily	Launched	Ticagrelor and its major metabolite reversibly interact with the platelet P2Y12 ADP-receptor to prevent signal transduction and platelet activation.	DD	Launched - ACUTE CORONARY SYNDROME	July 20, 2011	Launched	JAN12_3	AstraZeneca	5924466	JAN12_3	2011	2012
5923781	AZD0865	March 12, 2014					Discontinued	Gastric H+/K+-ATPase inhibitor	CCD	Discontinued - Acid-related gastrointestinal disorder; Phase II - Gastroesophageal reflux disease		Discontinued; Phase II	OCT11_4	ASTRAZENECA	5923781	OCT11_4	1995	2014
5923405	H-40502	May 29,2002					No Development	Antigastric	CCD	No Development - Gastroesophageal reflux; Discovery - Gastroesophageal reflux		No Development - Gastroesophageal reflux; Discovery - Gastroesophageal reflux	APR11_2	AstraZeneca plc	5923405	APR11_2	1995	2002
5923425	AZD4694	August 14, 2015					Phase III	Beta amyloid fibril inhibitor	CCD	Phase III - Alzheimer's disease; Phase II - Alzheimer's disease		Phase III; Phase II	AUG11_3	AstraZeneca Plc	5923425	AUG11_3	1995	2015
5923426	AZD5438	March 12, 2014		AZD5438 was discontinued owing to tolerability and exposure data from the studies			Discontinued	Anticancer	CCD	Discontinued - Solid tumor		Discontinued	AUG11_3	AstraZeneca Plc	5923426	AUG11_3	1995	2014
5923427	AZD7295	March 12, 2014					Discontinued	NS5A protein inhibitor	CCD	Discontinued - Hepatitis C		Discontinued	AUG11_3	AstraZeneca Plc	5923427	AUG11_3	1995	2014
5923428	AZD7687	March 13, 2014		Development was discontinued as clinical results not supporting the intended target product profileTPP.			Discontinued	Diacylglycerol acyltransferase inhibitor	CCD	Phase I - Obesity, Type-2 diabetes; Discontinued - Obesity, Type-2 diabetes		Phase I; Discontinued	AUG11_3	ASTRAZENECA PLC.	5923428	MAR14_4	1995	2014
5923428	AZD7687	March 13, 2014		Development was discontinued as clinical results not supporting the intended target product profileTPP.			Discontinued	Diacylglycerol acyltransferase inhibitor	CCD	Phase I - Obesity, Type-2 diabetes; Discontinued - Obesity, Type-2 diabetes		Phase I; Discontinued	AUG11_3	AstraZeneca Plc	5923428	AUG11_3	1995	2014
5923977	AZD5745	March 12, 2014					Discontinued	Antacid; Antiulcerant	CCD	Discontinued - Acid-related gastrointestinal disorder		Discontinued	OCT11_4	ASTRAZENECA PLC	5923977	OCT11_4	1995	2014
5921201	AZD-8055	March 12, 2014					Discontinued	mTOR inhibitor	CCD	Discontinued - Glioblastoma multiforme, Anaplastic astrocytoma, Anaplastic oligodendroglioma, Malignant glioma, Brainstem glioma, Advanced solid tumor, Lymphoma, Cancer		Discontinued	JAN12_3	ASTRAZENECA PLC.	5921201	JAN12_3	1995	2014
5923649	AZD-2461	May 15, 2012					Discontinued	Anticancer	CCD	Discontinued - Tumor; Phase I - Tumor		Discontinued; Phase I	AUG11_3	AstraZeneca Plc	5923649	AUG11_3	1995	2012
5923653	AZD5658	February 13, 2014		Development of AZD-5658 was discontinued due to lack of safety and efficacy profile.			Discontinued	Glucokinase activator	CCD	Phase I - OBESITY, TYPE-2 DIABETES; Discontinued - TYPE-2 DIABETES		Phase I; Discontinued	AUG11_3	ASTRAZENECA PLC.	5923653	AUG11_3	1995	2014
5923653	AZD5658	February 13, 2014		Development of AZD-5658 was discontinued due to lack of safety and efficacy profile.			Discontinued	Glucokinase activator	CCD	Phase I - OBESITY, TYPE-2 DIABETES; Discontinued - TYPE-2 DIABETES		Phase I; Discontinued	AUG11_3	AstraZeneca Plc	5923653	AUG11_3	1995	2014
5923654	AZD9819	August 14, 2015					No Development	Neutrophil elastase inhibitor	CCD	No Development - Asthma; Discontinued - Chronic obstructive pulmonary disease; Phase II - Asthma, Chronic obstructive pulmonary disease; Phase I - Chronic obstructive pulmonary disease		No Development; Discontinued; Phase II; Phase I	AUG11_3	AstraZeneca Plc	5923654	AUG11_3	1995	2015
5924330	[11C]-AZD-2184	June 30, 2015					Phase I	beta-Amyloid inhibitor	CCD	Phase I - Diagnosis of Alzheimer's Disease		Phase I	JAN12_3	AstraZeneca	5924330	JAN12_3	1995	2015
5923658	AZD-3514	March 12, 2014		Development of the drug was discontinued due to tolerability issues			Discontinued	Downregulates androgen receptor, inhibiting androgen receptor translocation resulting in proteasomal receptor protein degradation	CCD	Discontinued - Castration-resistant prostate cancer; Phase I - Castration-resistant prostate cancer		Discontinued; Phase I	AUG11_3	AstraZeneca Plc	5923658	AUG11_3	1995	2014
5923659	AZD-5213	August 14, 2015					Phase II	Histamine H3 receptor antagonist	CCD	Phase II - Tourette's syndrome, Neuropathic pain; No Development - Mild cognitive impairment, Attention-deficit hyperactivity disorder; Discontinued - Alzheimer's disease; Phase II - Alzheimer's disease; Phase I - Alzheimer's disease, Attention-deficit hyperactivity disorder		Phase II; No Development; Discontinued; Phase II; Phase I	AUG11_3	ASTRAZENECA PLC.	5923659	AUG11_3	1995	2015
5923659	AZD-5213	August 14, 2015					Phase II	Histamine H3 receptor antagonist	CCD	Phase II - Tourette's syndrome, Neuropathic pain; No Development - Mild cognitive impairment, Attention-deficit hyperactivity disorder; Discontinued - Alzheimer's disease; Phase II - Alzheimer's disease; Phase I - Alzheimer's disease, Attention-deficit hyperactivity disorder		Phase II; No Development; Discontinued; Phase II; Phase I	AUG11_3	AstraZeneca Plc	5923659	AUG11_3	1995	2015
5923660	AZD-5363	June 30, 2015					Phase II	AKT inhibitor	CCD	Phase II - Invasive breast cancer; Phase I - Advanced solid malignancy, Advanced cancer		Phase II; Phase I	AUG11_3	ASTRAZENECA PLC.	5923660	MAR14_4	1995	2015
5923660	AZD-5363	June 30, 2015					Phase II	AKT inhibitor	CCD	Phase II - Invasive breast cancer; Phase I - Advanced solid malignancy, Advanced cancer		Phase II; Phase I	AUG11_3	AstraZeneca Plc	5923660	AUG11_3	1995	2015
5923671	AZD4451	September 19, 2013					Phase I	Antidepressant; Antipsychotic	CCD	Phase I - Bipolar disorder		Phase I	AUG11_3	AstraZeneca Plc	5923671	AUG11_3	1995	2013
5924214	ARH047108	March 12, 2014					Discontinued	Proton pump inhibitor	CCD	Discontinued - Acid-related gastrointestinal disorder; Phase I - Acid-related gastrointestinal disorder		Discontinued; Phase I	OCT11_4	ASTRAZENECA	5924214	OCT11_4	1995	2014
5924397	ZD-6416	March 12, 2014					Discontinued	Prostaglandin EP1 receptor antagonist	CCD	Discontinued - Moderate pain		Discontinued	JAN12_3	Astra Zeneca	5924397	JAN12_3	1995	2014
5924400	ZM-374979	December 07,2011					Preclinical	Neurokinin receptor Antagonist	CCD	Preclinical - Asthama		Preclinical	JAN12_3	Astrazeneca	5924400	JAN12_3	1995	2011
15500490	KU-7059	March 8, 2013					Preclinical	DNA-dependent protein kinase inhibitor	CCD	Preclinical - Cancer; Discontinued - Cancer		Preclinical; Discontinued	Q1Q2	ASTRAZENECA PLC.	15500490	Q1Q2	1995	2013
15500492	NU-7499	December 04, 2009					Preclinical	DNA-dependent protein kinase inhibitor	CCD	Preclinical - Cancer; Discontinued - Cancer		Preclinical; Discontinued	Q1Q2	ASTRAZENECA PLC.	15500492	Q1Q2	1995	2009
15500493	NU-7511	December 04, 2009					Preclinical	DNA-dependent protein kinase inhibitor	CCD	Preclinical - Cancer; Discontinued - Cancer		Preclinical; Discontinued	Q1Q2	ASTRAZENECA PLC.	15500493	Q1Q2	1995	2009
15500495	NU-7523	December 04, 2009					Preclinical	DNA-dependent protein kinase inhibitor	CCD	Preclinical - Cancer; Discontinued - Cancer		Preclinical; Discontinued	Q1Q2	ASTRAZENECA PLC.	15500495	Q1Q2	1995	2009
15500496	NU-7536	December 04, 2009					Preclinical	DNA-dependent protein kinase inhibitor	CCD	Preclinical - Cancer; Discontinued - Cancer		Preclinical; Discontinued	Q1Q2	ASTRAZENECA PLC.	15500496	Q1Q2	1995	2009
15500804	AZ-11757790	9/26/2007					Preclinical	Coagulation factor Xa inhibitor; Coagulation inhibitor	CCD	Preclinical - Thrombosis		Preclinical	Q1Q2	ASTRAZENECA PLC.	15500804	Q1Q2	1995	2007
15500805	AZ-11639114	9/26/2007					Preclinical	Coagulation factor Xa inhibitor; Coagulation inhibitor	CCD	Preclinical - Thrombosis		Preclinical	Q1Q2	ASTRAZENECA PLC.	15500805	Q1Q2	1995	2007
15500806	AZ-12300547	9/26/2007					Preclinical	Coagulation factor Xa inhibitor; Coagulation inhibitor	CCD	Preclinical - Thrombosis		Preclinical	Q1Q2	ASTRAZENECA PLC.	15500806	Q1Q2	1995	2007
15500807	ZD-5227	August 06, 2008					No Development	Coagulation factor Xa antagonist; Coagulation inhibitor	CCD	No Development - Thrombosis; Discovery - Thrombosis		No Development; Discovery; Phase-36	Q1Q2	ASTRAZENECA PLC.	15500807	Q1Q2	1995	2008
15500808	AZ-12235743	9/26/2007					Preclinical	Coagulation factor Xa inhibitor; Coagulation inhibitor	CCD	Preclinical - Thrombosis		Preclinical	Q1Q2	ASTRAZENECA PLC.	15500808	Q1Q2	1995	2007
15500581	DAPAGLIFLOZIN + METFORMIN	March 04, 2014	PRESCRIPTION DRUG			5 mg/850 mg and 5 mg/1000 mg	Launched	Sodium/glucose cotransporter 2 inhibitor	DD	Launched - Type-2 diabetes; Phase III - Diabetes mellitus		Launched; Phase III	Q1Q2	ASTRAZENECA PLC.	15500581	MAR14_4	1995	2014
15500581	DAPAGLIFLOZIN + METFORMIN	March 04, 2014	PRESCRIPTION DRUG			5 mg/850 mg and 5 mg/1000 mg	Launched	Sodium/glucose cotransporter 2 inhibitor	DD	Launched - Type-2 diabetes; Phase III - Diabetes mellitus		Launched; Phase III	Q1Q2	ASTRAZENECA PLC	15500581	Q1Q2	1995	2014
17000160	D-5519	September 22, 2008		Withdrawn in UK due to gastrointestinal toxicity			Discontinued	Corticosteroid agonist; Arachidonic acid antagonist	CCD	Discontinued - Inflammatory disease, Asthma, Respiratory disease; Phase I - Asthma; Preclinical - Inflammatory disease, Respiratory disease		Phase I	Q3	ASTRA DRACO AB  ASTRAZENECA PLC.	17000160	Q3	1995	2008
17000025	AZD-2098	June 12, 2013		This drug was discontinued as a result of their failure to meet their target product profiles			Discontinued	Anti-inflammatory	CCD	Discontinued - Asthma		Discontinued; Phase I	Q3	ASTRAZENECA PLC.	17000025	Q3	1995	2013
17500581	AZD-6482	May 17, 2012					Discontinued	Phosphoinositide 3 kinase beta inhibitor; Platelet aggregation inhibitor; Coagulation inhibitor	CCD	Discontinued - Thrombosis; Phase I - Thrombosis		Discontinued; Phase I	Q4	ASTRAZENECA PLC.	17500581	Q4	1995	2012
16001361	AR-C17708AR	June 08, 2010					No Development	Inducible Nitric oxide synthase inhibitor	CCD	No Development - Inflammatory disease; Preclinical - Inflammatory disease		No Development; Preclinical	Q1Q2	ASTRAZENECA PLC.	16001361	Q1Q2	1995	2010
17500608	AZD-8566	June 12, 2013					Discontinued	Chemokine (C-C Motif) receptor 5 antagonist	CCD	Discontinued - Chronic Obstructive Pulmonary Disease		Discontinued	Q4	ASTRAZENECA PLC.	17500608	Q4	1995	2013
16000931	A-874	3/5/2007					Preclinical	NS5B polymerase inhibitor; RNA polymerase inhibitor	CCD	Preclinical - Hepatitis C virus infection		Preclinical	Q1Q2	ASTRAZENECA PLC	16000931	Q1Q2	1995	2007
16000931	A-874	3/5/2007					Preclinical	NS5B polymerase inhibitor; RNA polymerase inhibitor	CCD	Preclinical - Hepatitis C virus infection		Preclinical	Q1Q2	ASTRAZENECA PLC.	16000931	Q1Q2	1995	2007
16001771	A-058	August 12, 2009					Suspended	NS5B polymerase inhibitor	CCD	Suspended - Hepatitis C virus infection; Preclinical - Hepatitis C virus infection		Suspended; Preclinical	Q1Q2	ASTRAZENECA PLC.	16001771	Q1Q2	1995	2009
16001772	A-095	March 14, 2014					Suspended	NS5B polymerase inhibitor	CCD	Suspended - Hepatitis C virus infection; Preclinical - Hepatitis C virus infection		Suspended; Preclinical	Q1Q2	ASTRAZENECA PLC.	16001772	Q1Q2	1995	2014
16001773	A-166	3/5/2007					Preclinical	NS5B polymerase inhibitor	CCD	Preclinical - Hepatitis C virus infection		Preclinical	Q1Q2	ASTRAZENECA PLC.	16001773	Q1Q2	1995	2007
16001773	A-166	3/5/2007					Preclinical	NS5B polymerase inhibitor	CCD	Preclinical - Hepatitis C virus infection		Preclinical	Q1Q2	ASTRAZENECA PLC	16001773	Q1Q2	1995	2007
16001774	A-167	3/5/2007					Preclinical	NS5B polymerase inhibitor	CCD	Preclinical - Hepatitis C virus infection		Preclinical	Q1Q2	ASTRAZENECA PLC.	16001774	Q1Q2	1995	2007
16001774	A-167	3/5/2007					Preclinical	NS5B polymerase inhibitor	CCD	Preclinical - Hepatitis C virus infection		Preclinical	Q1Q2	ASTRAZENECA PLC	16001774	Q1Q2	1995	2007
16001815	A-168	3/5/2007					Preclinical	NS5B polymerase inhibitor	CCD	Preclinical - Hepatitis C virus infection		Preclinical	Q1Q2	ASTRAZENECA PLC.	16001815	Q1Q2	1995	2007
16001815	A-168	3/5/2007					Preclinical	NS5B polymerase inhibitor	CCD	Preclinical - Hepatitis C virus infection		Preclinical	Q1Q2	ASTRAZENECA PLC	16001815	Q1Q2	1995	2007
16000433	GKA-50	3/20/2008					Preclinical	Glucokinase activator	CCD	Preclinical - Diabetes mellitus		Preclinical	Q1Q2	ASTRAZENECA PLC.	16000433	Q1Q2	1995	2008
16001816	A-169	3/5/2007					Preclinical	NS5B polymerase inhibitor	CCD	Preclinical - Hepatitis C virus infection		Preclinical	Q1Q2	ASTRAZENECA PLC.	16001816	Q1Q2	1995	2007
16001816	A-169	3/5/2007					Preclinical	NS5B polymerase inhibitor	CCD	Preclinical - Hepatitis C virus infection		Preclinical	Q1Q2	ASTRAZENECA PLC	16001816	Q1Q2	1995	2007
17000485	AR-D-111421	3/24/2004					Discontinued	Vasoactive intestinal polypeptide receptor agonist	CCD	Discontinued - Asthma; Phase 2 - Asthma		Phase II	Q3	ASTRAZENECA PLC.	17000485	Q3	1995	2004
17000497	AZD-4407	3/22/2007					Discontinued	5-Lipoxygenase inhibitor	CCD	Phase I - Chronic obstructive pulmonary disease; Preclinical - Chronic obstructive pulmonary disease, Inflammatory disease, Asthma; Discontinued - Chronic obstructive pulmonary disease		Phase I	Q3	ASTRAZENECA PLC.	17000497	Q3	1995	2007
17000508	AR-C78511	8/6/2008					No Development	P2Y Purinoceptor 12 antagonist	CCD	No Development - Thrombosis; Preclinical - Thrombosis		Discontinued; Preclinical	Q3	ASTRAZENECA PLC.	17000508	Q3	1995	2008
17000509	AZ-11931285	8/6/2008					No Development	P2Y Purinoceptor 12 antagonist	CCD	No Development - Thrombosis; Preclinical - Thrombosis		Discontinued; Preclinical	Q3	ASTRAZENECA PLC.	17000509	Q3	1995	2008
16001156	A-640	3/5/2007					Preclinical	NS5B polymerase inhibitor; RNA polymerase inhibitor	CCD	Preclinical - Hepatitis C virus infection		Preclinical	Q1Q2	ASTRAZENECA PLC.	16001156	Q1Q2	1995	2007
16001156	A-640	3/5/2007					Preclinical	NS5B polymerase inhibitor; RNA polymerase inhibitor	CCD	Preclinical - Hepatitis C virus infection		Preclinical	Q1Q2	ASTRAZENECA PLC	16001156	Q1Q2	1995	2007
16001157	A-644	3/5/2007					Preclinical	NS5B polymerase inhibitor; RNA polymerase inhibitor	CCD	Preclinical - Hepatitis C virus infection		Preclinical	Q1Q2	ASTRAZENECA PLC.	16001157	Q1Q2	1995	2007
16001157	A-644	3/5/2007					Preclinical	NS5B polymerase inhibitor; RNA polymerase inhibitor	CCD	Preclinical - Hepatitis C virus infection		Preclinical	Q1Q2	ASTRAZENECA PLC	16001157	Q1Q2	1995	2007
16001158	A-972	3/5/2007					Preclinical	NS5B polymerase inhibitor; RNA polymerase inhibitor	CCD	Preclinical - Hepatitis C virus infection		Preclinical	Q1Q2	ASTRAZENECA PLC.	16001158	Q1Q2	1995	2007
16001158	A-972	3/5/2007					Preclinical	NS5B polymerase inhibitor; RNA polymerase inhibitor	CCD	Preclinical - Hepatitis C virus infection		Preclinical	Q1Q2	ASTRAZENECA PLC	16001158	Q1Q2	1995	2007
17000242	AZD-2858	June 12, 2013		AstraZeneca plc. had discontinued the development of AZD-2858 as a result of their failure to meet the target product profile			Discontinued	Glycogen synthase kinase 3 inhibitor	CCD	Discontinued - Alzheimer's disease		Discontinued	Q3	ASTRAZENECA PLC.	17000242	Q3	1995	2013
17000512	AR-C118537XX	8/6/2008					No Development	P2Y Purinoceptor 12 antagonist	CCD	No Development - Thrombosis; Preclinical - Thrombosis		Discontinued; Preclinical	Q3	ASTRAZENECA PLC.	17000512	Q3	1995	2008
17000513	AR-C69581	June 12, 2013					No Development	P2Y Purinoceptor 12 partial inverse agonist	CCD	No Development - Thrombosis; Preclinical - Thrombosis		Discontinued; Preclinical	Q3	ASTRAZENECA PLC.	17000513	Q3	1995	2013
17000084	D-5272	7/30/2002					Discontinued	Steroid hormone receptor agonist	CCD	Discontinued - Asthma; Phase II - Asthma		Phase II	Q3	ASTRA DRACO AB  ASTRAZENECA PLC	17000084	Q3	1995	2002
17000089	ITROCINONIDE	9/27/2002					Discontinued	Glucocorticoid receptor agonist	CCD	Discontinued - Asthma		Discontinued	Q3	ASTRA AB  ASTRAZENECA PLC.	17000089	Q3	1995	2002
16000990	GKA-22	3/20/2008					Preclinical	Glucokinase activator	CCD	Preclinical - Diabetes mellitus		Preclinical	Q1Q2	ASTRAZENECA PLC.	16000990	Q1Q2	1995	2008
16000997	GKA-30	3/20/2008					Preclinical	Glucokinase activator	CCD	Preclinical - Diabetes mellitus		Preclinical	Q1Q2	ASTRAZENECA PLC.	16000997	Q1Q2	1995	2008
16000998	GKA-31	3/20/2008					Preclinical	Glucokinase activator	CCD	Preclinical - Diabetes mellitus		Preclinical	Q1Q2	ASTRAZENECA PLC.	16000998	Q1Q2	1995	2008
16000999	AR-025028	August 14, 2009					Preclinical	Glycogen synthase kinase 3 inhibitor	CCD	Preclinical - Alzheimer's disease		Preclinical	Q1Q2	ASTRAZENECA AB	16000999	Q1Q2	1995	2009
16001001	SN-2127	4/14/2008					Preclinical	Glycogen synthase kinase 3 inhibitor	CCD	Preclinical - Alzheimer's disease		Preclinical	Q1Q2	ASTRAZENECA AB	16001001	Q1Q2	1995	2008
16001002	SN-3728	4/14/2008					Preclinical	Glycogen synthase kinase 3 inhibitor	CCD	Preclinical - Alzheimer's disease		Preclinical	Q1Q2	ASTRAZENECA AB	16001002	Q1Q2	1995	2008
16001616	A-448	3/5/2007					Preclinical	NS5B polymerase inhibitor	CCD	Preclinical - Hepatitis C virus infection		Preclinical	Q1Q2	ASTRAZENECA PLC.	16001616	Q1Q2	1995	2007
16001617	A-510	3/5/2007					Preclinical	NS5B polymerase inhibitor	CCD	Preclinical - Hepatitis C virus infection		Preclinical	Q1Q2	ASTRAZENECA PLC.	16001617	Q1Q2	1995	2007
16001617	A-510	3/5/2007					Preclinical	NS5B polymerase inhibitor	CCD	Preclinical - Hepatitis C virus infection		Preclinical	Q1Q2	ASTRAZENECA PLC	16001617	Q1Q2	1995	2007
16001618	A-521	3/5/2007					Preclinical	NS5B polymerase inhibitor	CCD	Preclinical - Hepatitis C virus infection		Preclinical	Q1Q2	ASTRAZENECA PLC.	16001618	Q1Q2	1995	2007
16001618	A-521	3/5/2007					Preclinical	NS5B polymerase inhibitor	CCD	Preclinical - Hepatitis C virus infection		Preclinical	Q1Q2	ASTRAZENECA PLC	16001618	Q1Q2	1995	2007
16001619	A-524	3/5/2007					Preclinical	NS5B polymerase inhibitor	CCD	Preclinical - Hepatitis C virus infection		Preclinical	Q1Q2	ASTRAZENECA PLC.	16001619	Q1Q2	1995	2007
16001619	A-524	3/5/2007					Preclinical	NS5B polymerase inhibitor	CCD	Preclinical - Hepatitis C virus infection		Preclinical	Q1Q2	ASTRAZENECA PLC	16001619	Q1Q2	1995	2007
16001623	A-850	3/5/2007					Preclinical	NS5B polymerase inhibitor	CCD	Preclinical - Hepatitis C virus infection		Preclinical	Q1Q2	ASTRAZENECA PLC.	16001623	Q1Q2	1995	2007
17000517	AR-C120215XX	8/6/2008					No Development	P2Y Purinoceptor 12 antagonist	CCD	No Development - Thrombosis; Preclinical - Thrombosis		Discontinued; Preclinical	Q3	ASTRAZENECA PLC.	17000517	Q3	1995	2008
17000518	AR-C70300	8/6/2008					No Development	P2Y Purinoceptor 12 antagonist	CCD	No Development - Thrombosis; Preclinical - Thrombosis		Discontinued; Preclinical	Q3	ASTRAZENECA PLC.	17000518	Q3	1995	2008
17500479	PL-3233	March 24, 2010					Preclinical	Melanocortin 4 receptor agonist	CCD	Preclinical - Syndrome X, Erectile dysfunction, Obesity, Diabetes mellitus; Discontinued - Erectile dysfunction		Preclinical; Discontinued	Q4	ASTRAZENECA PLC.; PALATIN TECHNOLOGIES INC.	17500479	Q4	1995	2010
17500481	PT-15	March 24, 2010					Preclinical	Melanocortin 4 receptor agonist	CCD	Preclinical - Syndrome X, Erectile dysfunction, Obesity, Diabetes mellitus; Discontinued - Erectile dysfunction		Preclinical; Discontinued	Q4	ASTRAZENECA PLC.; PALATIN TECHNOLOGIES INC.	17500481	Q4	1995	2010
16001669	A-526	3/5/2007					Preclinical	NS5B polymerase inhibitor; RNA polymerase inhibitor	CCD	Preclinical - Hepatitis C virus infection		Preclinical	Q1Q2	ASTRAZENECA PLC.	16001669	Q1Q2	1995	2007
16001669	A-526	3/5/2007					Preclinical	NS5B polymerase inhibitor; RNA polymerase inhibitor	CCD	Preclinical - Hepatitis C virus infection		Preclinical	Q1Q2	ASTRAZENECA PLC	16001669	Q1Q2	1995	2007
16001670	A-629	3/5/2007					Preclinical	NS5B polymerase inhibitor; RNA polymerase inhibitor	CCD	Preclinical - Hepatitis C virus infection		Preclinical	Q1Q2	ASTRAZENECA PLC.	16001670	Q1Q2	1995	2007
16001670	A-629	3/5/2007					Preclinical	NS5B polymerase inhibitor; RNA polymerase inhibitor	CCD	Preclinical - Hepatitis C virus infection		Preclinical	Q1Q2	ASTRAZENECA PLC	16001670	Q1Q2	1995	2007
17000004	FPL-68164	4/7/1999					Discontinued	Antiasthmatic	CCD	Discontinued - Asthma; Preclinical - Asthma		Discontinued; Preclinical	Q3	ASTRA R& D CHARNWOOD  ASTRAZENECA PLC.	17000004	Q3	1995	1999
16001264	AR-C85016	7/3/2007					Preclinical	Inducible Nitric oxide synthase inhibitor; Endothelial nitric oxidase synthase inhibitor; Neuronal nitric oxide synthase inhibitor	CCD	Preclinical - Inflammatory disease		Preclinical	Q1Q2	ASTRAZENECA PLC.	16001264	Q1Q2	1995	2007
17600161	AZ-4175	12/22/2005					No Development	Immunomodulator	CCD	Preclinical - rheumatoid, Arthritis, Transplant rejection; No Development - rheumatoid, Arthritis, Transplant rejection		Preclinical; No Development	Q2_SEP09	ASTRAZENECA PLC.	17600161	Q2_SEP09	1995	2005
17600162	AZ-977	12/22/2005					No Development	Immunomodulator	CCD	No Development - rheumatoid, Arthritis, Transplant rejection; Preclinical - rheumatoid, Arthritis, Transplant rejection		No Development; Preclinical	Q2_SEP09	ASTRAZENECA PLC.	17600162	Q2_SEP09	1995	2005
30001019	SM-324405	July 5, 2013					Preclinical	Toll-like receptor 7 agonist	CCD	Preclinical - Asthma		Preclinical	MAY12_1	ASTRAZENECA PLC	30001019	MAY12_1	1995	2013
30002034	BACMECILLINAM	September 24, 1996	PRESCRIPTION DRUG				Launched	Cell wall synthesis inhibitor	DD	Launched - Bacterial infection		Launched	APR13_3	ASTRA PHARMACEUTICALS LTD.	30002034	APR13_3	1995	1996
30002050	AZD-0635	April 04, 2012					Preclinical		CCD	Preclinical - Waldenstrom macroglobulinemia		Preclinical	OCT12_4	ASTRAZENECA PLC.	30002050	OCT12_4	1995	2012
17500833	AZD-1704	June 23, 2008		AstraZeneca plc. has discontinued the compound			Discontinued	Cannabinoid receptor 1 agonist	CCD	Discontinued - Pain; Phase I - Pain; Preclinical - Pain		Discontinued; Phase I; Preclinical	Q4	ASTRAZENECA PLC.	17500833	Q4	1995	2008
17501760	AR-R18565	1/1/2004					No Development	Calcium channel blocker	CCD	Preclinical - Ischemia; No Development - Ischemia		Preclinical; No Development	DD-JUN-09	ASTRAZENECA PLC.	17501760	DD-JUN-09	1995	2004
17600073	AZD-2423	January 30, 2015		Discontinued due to lack of safety/efficacy			Discontinued	C-C chemokine receptor 2 antagonist	CCD	Discontinued - NEUROPATHIC PAIN, CHRONIC OBSTRUCTIVE PULMONARY DISEASE; Phase II - NEUROPATHIC PAIN, CHRONIC OBSTRUCTIVE PULMONARY DISEASE		Discontinued; Phase II	Q2_SEP09	ASTRAZENECA PLC	17600073	FEB15	1995	2015
17600073	AZD-2423	January 30, 2015		Discontinued due to lack of safety/efficacy			Discontinued	C-C chemokine receptor 2 antagonist	CCD	Discontinued - NEUROPATHIC PAIN, CHRONIC OBSTRUCTIVE PULMONARY DISEASE; Phase II - NEUROPATHIC PAIN, CHRONIC OBSTRUCTIVE PULMONARY DISEASE		Discontinued; Phase II	Q2_SEP09	ASTRAZENECA PLC.	17600073	Q2_SEP09	1995	2015
17600074	AZD-6714	June 12, 2013		Part A reached a predefined stopping criteria. Relevant doses for part B could not be established based on A and subsequently study was stopped			Discontinued	Glucokinase activator	CCD	Discontinued - Diabetes		Discontinued	Q2_SEP09	ASTRAZENECA PLC.	17600074	Q2_SEP09	1995	2013
30002180	PSN-842	December 21, 2011					Preclinical	G-protein coupled receptor-119 agonist	CCD	Preclinical - Obesity, Type-2 diabetes		Preclinical	OCT12_4	ASTRAZENECA	30002180	OCT12_4	1995	2011
30000893	AZD-2115	May 17, 2012					Phase II	Bronchodilator	CCD	Phase II - Chronic obstructive pulmonary disease; Phase I - Chronic obstructive pulmonary disease		Phase II; Phase I	MAY12_1	ASTRAZENECA	30000893	MAY12_1	1995	2012
30000894	AZD-2927	September 18, 2015					Discontinued	Ion channel modulator	CCD	Discontinued - Atrial fibrillation; Phase II - Atrial fibrillation		Discontinued; Phase II	MAY12_1	ASTRAZENECA	30000894	MAY12_1	1995	2015
30000895	AZD-3839	June 30, 2015		Development of AZD-3839 has been discontinued for safety and efficacy reasons.			Discontinued	BACE inhibitor	CCD	Discontinued - Alzheimer's disease; Phase I - Alzheimer's disease		Discontinued; Phase I	MAY12_1	ASTRAZENECA	30000895	MAY12_1	1995	2015
16001413	AR-C133057-XX	7/3/2007					Preclinical	Inducible Nitric oxide synthase inhibitor; Endothelial nitric oxidase synthase inhibitor; Neuronal nitric oxide synthase inhibitor	CCD	Preclinical - Inflammatory disease		Preclinical	Q1Q2	ASTRAZENECA PLC.	16001413	Q1Q2	1995	2007
30001361	AZD-2820	September 21, 2012					Discontinued	Melanocortin receptor agonist	CCD	Discontinued - Obesity		Discontinued	MAY12_1	ASTRAZENECA	30001361	MAY12_1	1995	2012
30001419	Benzoyl Metronidazole						Launched		DD	Launched - Antimicrobial		Launched	OCT12_4	ASTRAZENECA PLC.	30001419	OCT12_4	1995	1995
30001968	AZD-3965	April 05, 2012					Phase II	Monocarboxylate transporter-1 inhibitor	CCD	Phase I - Cancer; Phase II - Cancer		Phase I; Phase II	OCT12_4	ASTRAZENECA PLC.	30001968	OCT12_4	1995	2012
17502000	AZD-8529	June 12, 2013					Discontinued	Glutamate receptor modulator	CCD	Discontinued - Schizophrenia		Discontinued; Phase II	DD-JUN-09	ASTRAZENECA PLC.	17502000	DD-JUN-09	1995	2013
30003814	Bertilimumab	December 31, 2013					Phase II	CC Chemokine ligand 11 inhibitor	CCD	Phase II - Ulcerative Colitis; Phase I - Asthma, Bullous Pemphigoid, Crohn's Disease, Ophthalmic diseases		Phase II; Phase I	JUN12	ASTRAZENECA PLC	30003814	JUN12	1995	2013
30003815	Moxetumomab pasudotox	December 31, 2013					Phase III	CD22 inhibitor	CCD	Phase III - Hairy cell leukemia; Phase II - Non-Hodgkin's lymphoma, Chronic lymphocytic leukemia		Phase III; Phase II	JUN12	ASTRAZENECA PLC	30003815	JUN12	1995	2013
30002846	661479	April 30, 2009					Preclinical	c-MET tyrosine kinase inhibitor;AXL RECEPTOR TYROSINE KINASE INHIBITOR	CCD	Preclinical - Cancer		Preclinical	JUL12_3	ASTRAZENECA AB	30002846	JUL12_3	1995	2009
30005323	NAS-438	March 13, 2013					Preclinical	5-hydroxytryptamine 1D receptor antagonist; 5-Hydroxytryptamine 1B receptor antagonist	CCD	Preclinical - Cns disorder		Preclinical	APR13_3	ASTRAZENECA	30005323	APR13_3	1995	2013
30005494	AZD-5106	September 03, 2012					Discontinued	NK2 receptor antagonist	CCD	Discontinued - OVERACTIVE BLADDER SYNDROME		Discontinued	JAN13_3	ASTRAZENECA PLC	30005494	JAN13_3	1995	2012
30003009	660964	June 07, 2012					Preclinical		CCD	Preclinical - Inflammation		Preclinical	JUL12_3	ASTRAZENECA	30003009	JUL12_3	1995	2012
30003010	660965	June 13, 2012					Preclinical		CCD	Preclinical - Inflammatory disease		Preclinical	JUL12_3	ASTRAZENECA	30003010	JUL12_3	1995	2012
30005107	AR-C70484XX	July 30, 2012					Preclinical	Cytosolic phospholipase A2 inhibitor	CCD	Preclinical - Inflammatory disease		Preclinical	JAN13_3	ASTRAZENECA AB	30005107	JAN13_3	1995	2012
30106880	AZ-311	November 05, 2012					Preclinical		CCD	Preclinical - Neuropathic pain		Preclinical	JAN13_3	ASTRAZENECA	30106880	JAN13_3	1995	2012
30106881	AZ-685	October 31, 2012					Preclinical	Tachykinin receptor 2 antagonist	CCD	Preclinical - Neuropathic pain		Preclinical	APR13_3	ASTRAZENECA AB	30106881	APR13_3	1995	2012
30005135	AR-C85095MX	July 31, 2012					Preclinical	P2Y2 RECEPTOR ANTAGONIST	CCD	Preclinical - Asthma, Arthritis, Inflammation, Connective tissue disease, Musculoskeletal disorder		Preclinical	OCT12_4	ASTRAZENECA AB	30005135	OCT12_4	1995	2012
30002847	661480	April 30, 2009					Preclinical	c-Met inhibitor;AXL RECEPTOR TYROSINE KINASE INHIBITOR	CCD	Preclinical - Cancer		Preclinical	JUL12_3	ASTRAZENECA AB	30002847	JUL12_3	1995	2009
30002848	661481	May 21, 2012					Preclinical	c-Met inhibitor;AXL RECEPTOR TYROSINE KINASE INHIBITOR	CCD	Preclinical - Cancer		Preclinical	JUL12_3	ASTRAZENECA AB	30002848	JUL12_3	1995	2012
30002849	661485	April 30, 2009					Preclinical		CCD	Preclinical - Cancer		Preclinical	JUL12_3	ASTRAZENECA PLC	30002849	JUL12_3	1995	2009
30002850	661486	April 30, 2009					Preclinical		CCD	Preclinical - Cancer		Preclinical	JUL12_3	ASTRAZENECA PLC	30002850	JUL12_3	1995	2009
30002851	661498	April 24, 2012					Preclinical		CCD	Preclinical - Cancer		Preclinical	JUL12_3	ASTRAZENECA PLC	30002851	JUL12_3	1995	2012
30002332	ARC-126313	June 04, 2012					Preclinical	P2Y2 RECEPTOR ANTAGONIST	CCD	Preclinical - Hypertension, Congestive heart failure		Preclinical	JUL12_3	ASTRAZENECA	30002332	JUL12_3	1995	2012
30006640	KU-0063794	June 26, 2012					No Development	mTOR inhibitor	CCD	No Development - Cancer		No Development	JAN13_3	ASTRAZENECA AB	30006640	JAN13_3	1995	2012
30004555	AZ-628	July 05, 2012					Preclinical	Raf kinase inhibitor	CCD	Preclinical - Cancer		Preclinical	JAN13_3	ASTRAZENECA R&D	30004555	JAN13_3	1995	2012
30004574	AZ-11645373	July 05, 2012					Preclinical	P2X7 purinoceptor antagonist	CCD	Preclinical - ARTHRITIS, NEUROPATHIC PAIN, INFLAMMATORY PAIN		Preclinical	JAN13_3	ASTRAZENECA PHARMACEUTICALS	30004574	JAN13_3	1995	2012
30002333	ARC-118925	April 12, 2012					Preclinical	P2Y2 RECEPTOR ANTAGONIST	CCD	Preclinical - Inflammatory disease		Preclinical	OCT12_4	ASTRAZENECA AB	30002333	OCT12_4	1995	2012
30005581	AP-811	September 05, 2012					Preclinical	Atrial natriuretic peptide C receptor  antagonist	CCD	Preclinical - Diuresis		Preclinical	JAN13_3	ASTRAZENECA	30005581	JAN13_3	1995	2012
30005582	ARH-044178	September 05, 2012					Preclinical	Coagulation factor VIIA inhibitor	CCD	Preclinical - THROMBOTIC DISORDER		Preclinical	JAN13_3	ASTRAZENECA	30005582	JAN13_3	1995	2012
30106579	NCR-631	November 29, 2012					Preclinical	3-Hydroxyanthranilic acid 3,4-dioxygenase inhibitor	CCD	Preclinical - Cerebrovascular disease		Preclinical	JAN13_3	ASTRA ARCUS AB	30106579	JAN13_3	1995	2012
30005952	NCQ-318	March 13, 2013					Preclinical	Dopamine D1 receptor antagonist	CCD	Preclinical - Psychiatric disorder		Preclinical	APR13_3	ASTRAZENECA	30005952	APR13_3	1995	2013
30002748	661194	April 19, 2012					Preclinical	P2X7 purinoceptor antagonist	CCD	Preclinical - Arthritis, Inflammatory bowel disease, Rheumatoid arthritis		Preclinical	JUL12_3	ASTRAZENECA AB	30002748	JUL12_3	1995	2012
30004322	FPL-14294	July 01, 2012					Preclinical	Cholecystokinin receptor agonist	CCD	Preclinical - Eating disorder		Preclinical	JAN13_3	ASTRA ARCUS USA	30004322	JAN13_3	1995	2012
30003099	ARH-050642	May 18, 2012					Discontinued	ATP-sensitive potassium channel blocker	CCD	Preclinical - Arrhythmia; Discontinued - Arrhythmia		Preclinical; Discontinued	OCT12_4	ASTRAZENECA PLC	30003099	OCT12_4	1995	2012
30005614	AZD-0275	September 05, 2012					Discontinued	Chemokine receptor antagonist	CCD	Discontinued - Chronic Obstructive Pulmonary Disease		Discontinued	JAN13_3	ASTRAZENECA PLC	30005614	JAN13_3	1995	2012
30005615	AZD-0303	September 05, 2012		Failure to meet the target product profile			Discontinued		CCD	Discontinued - Thrombosis		Discontinued	JAN13_3	ASTRA ZENECA PLC	30005615	JAN13_3	1995	2012
30005616	AZD-0902	January 03, 2013		AstraZeneca announced on 28 July 2005 that it has ceased development of AZD 0902, which had potential for the treatment of rheumatoid arthritis, because the agent did not meet the required target product profile.			Discontinued	Ion channel blocker	CCD	Discontinued - RHEUMATOID ARTHRITIS, CHRONIC OBSTRUCTIVE PULMONARY DISEASE		Discontinued	JUL13_4	ASTRAZENECA PLC.	30005616	JUL13_4	1995	2013
30005617	AZD-1134	May 06, 2013					Discontinued	5-Hydroxytryptamine 1B receptor antagonist	CCD	Discontinued - ANXIETY, DEPRESSION		Discontinued	JUL13_4	ASTRAZENECA PLC	30005617	JUL13_4	1995	2013
30005618	AZD-2315	December 31, 2012		AstraZeneca has discontinued the development of AZD2315 for Rheumatoid Arthritis as a result of its failure to meet the target product profile			Discontinued	HLA Class II histocompatibility antigen DR-1 beta chain (HLA-DRB1) antagonist	CCD	Discontinued - Rheumatoid arthritis		Discontinued	JUL13_4	ASTRAZENECA PLC.	30005618	JUL13_4	1995	2012
30005619	AZD-3841	September 04, 2012					Discontinued		CCD	Discontinued - Solid tumor		Discontinued	JAN13_3	ASTRAZENECA PLC	30005619	JAN13_3	1995	2012
30005620	AZD-7806	September 04, 2012		AstraZeneca has discontinued the development of AZD-7806 for dyslipidaemia as a result of its failure to meet the target product profile			Discontinued	Ileal sodium/bile acid cotransporter inhibitor	CCD	Discontinued - Dyslipidemia		Discontinued	JUL13_4	ASTRAZENECA	30005620	JUL13_4	1995	2012
30005634	ZD-4953	September 11, 2012					Discontinued	Prostaglandin EP1 receptor antagonist	CCD	Discontinued - HYPERALGESIA, POST-OPERATIVE PAIN		Discontinued	JAN13_3	ASTRAZENECA PLC.	30005634	JAN13_3	1995	2012
30005635	ZD-6804	September 10, 2012					Discontinued	Prostaglandin EP1 receptor antagonist	CCD	Discontinued - Pain		Discontinued	JAN13_3	ASTRAZENECA PHARMACEUTICALS	30005635	JAN13_3	1995	2012
30005636	ZD-9720	September 10, 2012					Discontinued	Oxidosqualene cyclase inhibitor	CCD	Discontinued - Hypercholesterolemia		Discontinued	JAN13_3	ASTRAZENECA AB	30005636	JAN13_3	1995	2012
30006274	AZ-599	June 12, 2012					Preclinical	Cannabinoid receptor agonist	CCD	Preclinical - Inflammatory pain		Preclinical	OCT12_4	ASTRAZENECA AB	30006274	OCT12_4	1995	2012
30006292	AZ-960	June 13, 2012					Preclinical	Janus kinase 2 inhibitor	CCD	Preclinical - Cancer		Preclinical	OCT12_4	ASTRAZENECA AB	30006292	OCT12_4	1995	2012
30004330	NPY-5RA-972	July 23, 2012					Preclinical	Neuropeptide Y5 receptor antagonist	CCD	Preclinical - Obesity		Preclinical	JAN13_3	ASTRAZENECA AB	30004330	JAN13_3	1995	2012
30004343	AZD-5597	June 29, 2012					No Development	Cyclin-dependent kinase inhibitor	CCD	Preclinical - CANCER; No Development - CANCER		Preclinical	JAN13_3	ASTRAZENECA PHARMACEUTICALS	30004343	JAN13_3	1995	2012
30001233	Levomoprolol		PRESCRIPTION DRUG				Launched		DD	Launched		Launched	MAY12_1	ASTRA ZENECA	30001233	MAY12_1	1995	1995
30001251	AZD-9773	September 18, 2015					Discontinued	TNF alpha inhibitor	CCD	Discontinued - Severe sepsis; Phase II - Severe sepsis		Discontinued; Phase II	MAY12_1	ASTRAZENECA	30001251	MAY12_1	1995	2015
30004751	GPI-688	December 06, 2012					Preclinical	Glycogen phosphorylase inhibitor	CCD	Preclinical - Type-2 diabetes		Preclinical	JAN13_3	ASTRAZENECA	30004751	JAN13_3	1995	2012
30006107	AZ-Tak-1	October 15, 2012					Preclinical	TGF-beta receptor kinase-1 inhibitor	CCD	Preclinical - LYMPHOMA		Preclinical	SEP13_4	ASTRAZENECA	30006107	SEP13_4	1995	2012
30106958	FI-1831	December 26, 2013					Preclinical		CCD	Preclinical - DERMATOLOGICAL DISORDER		Preclinical	JAN14_5	ASTRAZENECA PLC.	30106958	JAN14_5	1995	2013
30106978	ARH-069927	October 30, 2012					Preclinical	MULTIDRUG AND TOXIN EXTRUSION PROTEIN 1 INHIBITOR	CCD	Preclinical - COAGULATION DISORDERS		Preclinical	APR13_3	ASTRAZENECA AB	30106978	APR13_3	1995	2012
30107836	AZD-1419	March 28, 2016					Phase I	TOLL-LIKE RECEPTOR 9 AGONIST	CCD	Phase I - Asthma		Phase I	APR13_3	ASTRAZENECA	30107836	APR16	1995	2016
30107836	AZD-1419	March 28, 2016					Phase I	TOLL-LIKE RECEPTOR 9 AGONIST	CCD	Phase I - Asthma		Phase I	APR13_3	ASTRA ZENECA PLC	30107836	APR13_3	1995	2016
30111930	A-692345	March 07, 2013					Preclinical		CCD	Preclinical - Bacterial Infection		Preclinical	JUL13_4	ASTRAZENECA AB	30111930	JUL13_4	1995	2013
30107924	AZD-3118	November 27, 2012					Discontinued		CCD	Discontinued - Arrhythmia		Discontinued	JAN13_3	ASTRA ZENECA PLC	30107924	JAN13_3	1995	2012
30107925	AZD-7140	January 17, 2013		AstraZeneca has discontinued the development of AZD7140 as a result of their failure to meet the target profile.			Discontinued	Chemokine receptor antagonist	CCD	Phase I - RHEUMATOID ARTHRITIS; Discontinued - RHEUMATOID ARTHRITIS, CHRONIC OBSTRUCTIVE PULMONARY DISEASE		Phase I; Discontinued	JUL13_4	ASTRAZENECA PLC.	30107925	JUL13_4	1995	2013
30107927	AZD-9139	December 17, 2012					Discontinued	H+ K+ ATPase inhibitor	CCD	Discontinued - Acid-related gastrointestinal disorder		Discontinued	APR13_3	ASTRA ZENECA PLC	30107927	APR13_3	1995	2012
30107928	MEDI-562	May 06, 2013					Discontinued	Hedgehog protein inhibitor	CCD	Discontinued - Solid tumor		Discontinued	JUL13_2	ASTRAZENECA PLC.	30107928	JUL13_2	1995	2013
17600230	AZD-6319	July 5, 2013					No Development	Nicotinic acetylcholine receptor alpha 7 agonist	CCD	No Development - Alzheimer's disease; Preclinical - Alzheimer's disease		No Development; Preclinical	Q2_SEP09	ASTRAZENECA PLC	17600230	Q2_SEP09	1995	2013
30108019	NU-6086	November 30, 2012					Preclinical	CDK1 inhibitor; CDK2 inhibitor	CCD	Preclinical - Cancer		Preclinical	JAN13_3	ASTRAZENECA	30108019	JAN13_3	1995	2012
30108020	NU-6094	November 28, 2012					Preclinical	CDK1 inhibitor; CDK2 inhibitor	CCD	Preclinical - Cancer		Preclinical	JAN13_3	ASTRAZENECA	30108020	JAN13_3	1995	2012
30002181	AZD-4316	November 01, 2010					Preclinical		CCD	Preclinical - CANCER, INFECTIOUS DISEASE		Preclinical	OCT13_4	ASTRAZENECA	30002181	OCT13_4	1995	2010
30002558	663170	May 10, 2012					Preclinical	Dipeptidyl peptidase 1 inhibitor	CCD	Preclinical - Asthma, Chronic obstructive pulmonary disease, Allergic rhinitis		Preclinical	JUL12_3	ASTRAZENECA	30002558	JUL12_3	1995	2012
30002559	663171	May 10, 2012					Preclinical	Dipeptidyl peptidase 1 inhibitor	CCD	Preclinical - Asthma, Allergic rhinitis, Chronic obstructive pulmonary disease		Preclinical	JUL12_3	ASTRAZENECA AB	30002559	JUL12_3	1995	2012
30002560	663172	May 10, 2012					Preclinical	Dipeptidyl peptidase 1 inhibitor	CCD	Preclinical - Asthma, Chronic obstructive pulmonary disease, Allergic rhinitis		Preclinical	JUL12_3	ASTRAZENECA AB	30002560	JUL12_3	1995	2012
30002561	663175	May 10, 2012					Preclinical	Dipeptidyl peptidase 1 inhibitor	CCD	Preclinical - Asthma, Allergic rhinitis, Chronic obstructive pulmonary disease		Preclinical	JUL12_3	ASTRAZENECA AB	30002561	JUL12_3	1995	2012
30002562	663176	May 10, 2012					Preclinical	Dipeptidyl peptidase 1 inhibitor	CCD	Preclinical - Asthma, Chronic obstructive pulmonary disease		Preclinical	JUL12_3	ASTRAZENECA PLC.	30002562	JUL12_3	1995	2012
30111011	AZD-3293	June 30, 2015					Phase III	As an inhibitor of the action of Beta-secretase enzyme, it could prevent the build up of beta-amyloid, which may help to slow the progression of, or stop, the disease	CCD	Phase III - Alzheimer's disease; Phase II - Alzheimer's disease; Phase I - Alzheimer's disease		Phase III; Phase II; Phase I	APR13_3	ASTRAZENECA PLC.	30111011	APR13_3	1995	2015
30005399	ZM-274773	August 29, 2012					Preclinical	NK2 receptor antagonist	CCD	Preclinical - ASTHMA, URINARY INCONTINENCE		Preclinical	JAN13_3	ASTRAZENECA PLC	30005399	JAN13_3	1995	2012
30106295	AZ-3146	September 27, 2012					Preclinical	Monopolar spindle 1 kinase inhibitor	CCD	Preclinical - Tumor		Preclinical	JAN13_3	ASTRAZENECA UK LTD	30106295	JAN13_3	1995	2012
30106296	AZ-12216052	November 28, 2012					Preclinical	Metabotropic glutamate receptor antagonist	CCD	Preclinical - Anxiety		Preclinical	SEP13_4	ASTRAZENECA PHARMACEUTICALS	30106296	SEP13_4	1995	2012
30107440	CHLORODYSINOSIN A	December 05, 2012					Preclinical	Thrombin inhibitor; Coagulation factor VIIA inhibitor; Factor Xa inhibitor	CCD	Preclinical - Platelet aggregation		Preclinical	SEP13_1	ASTRAZENECA PLC.	30107440	SEP13_1	1995	2012
30003728	CAM3001	December 31, 2013					Phase II	Colony stimulating factor 2 receptor alpha antagonist	CCD	Phase II - Rheumatoid arthritis		Phase II	JUN12	ASTRAZENECA PLC	30003728	JUN12	1995	2013
30003729	CAT354	August 14, 2015					Phase III	Interleukin 13 receptor blocker	CCD	Phase III - Asthma; Phase II - Alopecia areata, Atopic dermatitis; Discontinued - Chronic obstructive pulmonary disease, Idiopathic pulmonary fibrosis, Ulcerative colitis		Phase III; Phase II	JUN12	ASTRAZENECA PLC	30003729	JUN12	1995	2015
30115799	AZ-12908010	June 24, 2013					Preclinical	Fibroblast growth factor receptor inhibitor	CCD	Preclinical - HEAD AND NECK CANCER, NON-SMALL CELL LUNG CANCER		Preclinical	JUL13_4	ASTRAZENECA	30115799	JUL13_4	1995	2013
30003791	AZD-1208	September 24, 2013					Phase I	Pim oncogene inhibitor	CCD	Phase I - Acute myeloid leukemia, Advanced solid malignancies, Malignant lymphoma		Phase I	FEB14_4	ASTRAZENECA PLC	30003791	FEB14_4	1995	2013
30004129	AZD-7451	June 20, 2012					Preclinical	Neurotrophic tyrosine kinase receptor inhibitor	CCD	Preclinical - Cancer		Preclinical	FEB14_4	ASTRAZENECA AB	30004129	FEB14_4	1995	2012
30003856	AZD-4282	October 09, 2012					Discontinued		CCD	Discontinued - Solid tumor		Discontinued	FEB14_4	ASTRAZENECA	30003856	FEB14_4	1995	2012
30003857	AZD-4440	May 21, 2012		AstraZeneca plc. had discontinued the development of AZD-4440 due to failure to meet their target product profiles			Discontinued		CCD	Discontinued - Solid tumor		Discontinued	FEB14_4	ASTRAZENECA PLC	30003857	FEB14_4	1995	2012
30003858	AZD-4619	May 21, 2012					Discontinued	Peroxisome proliferator-activator receptor agonist	CCD	Discontinued - Dyslipidemia		Discontinued	FEB14_4	ASTRAZENECA PLC	30003858	FEB14_4	1995	2012
30003859	AZD-4750	May 21, 2012					Discontinued	Chemokine receptor antagonist	CCD	Discontinued - Multiple sclerosis		Discontinued	FEB14_4	ASTRAZENECA PLC	30003859	FEB14_4	1995	2012
30003861	AZD-5455	May 21, 2012					Discontinued		CCD	Discontinued - Anxiety		Discontinued	FEB14_4	ASTRAZENECA PLC	30003861	FEB14_4	1995	2012
30003862	AZD-6495	May 21, 2012					Discontinued	Colony stimulating factor 1 receptor antagonist	CCD	Discontinued - Solid tumor		Discontinued	FEB14_4	ASTRAZENECA PLC	30003862	FEB14_4	1995	2012
30003863	AZD-8294	May 21, 2012					Discontinued		CCD	Discontinued - Dyslipidemia		Discontinued	FEB14_4	ASTRAZENECA PLC	30003863	FEB14_4	1995	2012
30115155	AZ-11805131	June 09, 2013					Preclinical	DP2 receptor antagonist	CCD	Preclinical - Chronic Obstructive Pulmonary Disease		Preclinical	JUL13_2	ASTRAZENECA PLC.	30115155	JUL13_2	1995	2013
30006586	AZD-8955	August 07, 2012					Discontinued	Collagenase inhibitor	CCD	Discontinued - Osteoarthritis		Discontinued	FEB14_4	ASTRAZENECA PLC.	30006586	FEB14_4	1995	2012
30115578	AZD-2691	June 18, 2013					Preclinical	Cannabinoid CB1 receptor antagonist	CCD	Preclinical - OBESITY, DIABETES		Preclinical	SEP13_4	ASTRAZENECA	30115578	SEP13_4	1995	2013
30115212	AZ-11665362	June 10, 2013					Preclinical	CRTH2 antagonist	CCD	Preclinical - Allergy		Preclinical	JUL13_2	ASTRAZENECA PLC.	30115212	JUL13_2	1995	2013
30004042	CAT-5001	May 29, 2012					Discontinued	Mesothelin inhibitor	CCD	Discontinued - Solid tumor		Discontinued	FEB14_4	ASTRAZENECA PLC.	30004042	FEB14_4	1995	2012
30113469	AZ-505	April 22, 2013					Preclinical	SET AND MYND DOMAIN CONTAINING PROTEIN 2 INHIBITOR	CCD	Preclinical - CANCER		Preclinical	OCT13_4	ASTRAZENECA AB	30113469	OCT13_4	1995	2013
30004099	AMG-139	September 13, 2013					Phase II	Neutralizes IL-23 interaction with its receptor while sparing IL-12	CCD	Phase II - Crohn's disease; Phase I - Psoriasis		Phase II; Phase I	FEB14_4	ASTRAZENECA PLC.	30004099	FEB14_4	1995	2013
30004100	AMG-157	June 30, 2015					Phase II	Blocks the interaction of Thymic stromal lymphopoietin protein with Thymic stromal lymphopoietin protein receptor	CCD	Phase II - Asthma, Cat allergy; Phase I - Asthma, Atopic dermatitis		Phase II; Phase I	FEB14_4	ASTRAZENECA PLC.	30004100	FEB14_4	1995	2015
30114827	GKA-71	July 14, 2014					Preclinical	Glucokinase activator	CCD	Preclinical - Type-2 diabetes		Preclinical	JUL14_4	ASTRAZENECA PLC	30114827	JUL14_4	1995	2014
30115380	H-32786	July 08, 2014					Discontinued		CCD	Phase II - ATHEROSCLEROSIS; Discontinued - ATHEROSCLEROSIS		Phase II; Discontinued	JUL14_4	ASTRAZENECA	30115380	JUL14_4	1995	2014
30005912	FLB-463	May 26, 2014					Preclinical	Dopamine receptor D2 antagonist	CCD	Preclinical - Psychosis		Preclinical	JUN14_4	ASTRAZENECA PLC	30005912	JUN14_4	1995	2014
30005854	ARH-040922	September 12, 2012					Discontinued	Neuropeptide Y1 receptor antagonist	CCD	Phase I - ISCHEMIC HEART DISEASE; Discontinued - ISCHEMIC HEART DISEASE		Phase I; Discontinued	MAR14_4	ASTRAZENECA PLC	30005854	MAR14_4	1995	2012
30106977	ARH-067637	October 30, 2012					Preclinical	Thrombin inhibitor	CCD	Preclinical - COAGULATION DISORDERS		Preclinical	MAR14_4	ASTRAZENECA	30106977	MAR14_4	1995	2012
30116104	ARHO-47108	May 30, 2014					Preclinical	Proton pump (H+/K+-ATPase) inhibitor	CCD	Preclinical - Gastroesophageal Reflux Disease		Preclinical	JUN14_4	ASTRAZENECA	30116104	JUN14_4	1995	2014
30117630	[11C]-AZD-2995	May 23, 2014					Phase I	Beta amyloid modulator	CCD	Phase I - Alzheimer's disease		Phase I	JUN14_4	ASTRAZENECA PLC.	30117630	JUN14_4	1995	2014
30114525	AZD-8165	June 30, 2015					No Development	Thrombin inhibitor	CCD	No Development - Coagulation disorders; Phase I - Coagulation disorders		No Development; Phase I	JUL13_4	ASTRAZENECA	30114525	JUL13_4	1995	2015
30108233	ARC-109318-XX	January 17, 2013					Preclinical	P2Y12 receptor antagonist	CCD	Preclinical - Platelet aggregation		Preclinical	MAR14_4	ASTRAZENECA	30108233	MAR14_4	1995	2013
30108550	ARD-111421	December 19, 2012					Preclinical	Vasoactive intestinal polypeptide receptor agonist	CCD	Preclinical - Asthma		Preclinical	MAR14_4	ASTRAZENECA PLC.	30108550	MAR14_4	1995	2012
30111932	ARHO-29953-XX	April 24, 2013					Preclinical		CCD	Preclinical - VENOUS THROMBOEMBOLISM		Preclinical	MAR14_4	ASTRA HASSLE AB	30111932	MAR14_4	1995	2013
30005495	H-40922	May 06, 2014					Discontinued	Neuropeptide Y1 receptor antagonist	CCD	Phase II - ISCHEMIC HEART DISEASE; Discontinued - ISCHEMIC HEART DISEASE		Phase II; Discontinued	MAY14_5	ASTRAZENECA PLC	30005495	MAY14_5	1995	2014
30005637	ZD-7851	January 17, 2013					Discontinued	Oxidosqualene cyclase inhibitor	CCD	Discontinued - Hypercholesterolemia		Discontinued	MAY14_5	ASTRAZENECA PHARMACEUTICALS	30005637	MAY14_5	1995	2013
16001412	AR-C102222	June 15, 2015					Discontinued	Inducible Nitric oxide synthase inhibitor; Endothelial nitric oxidase synthase inhibitor; Neuronal nitric oxide synthase inhibitor	CCD	Discontinued - Inflammatory disease; Preclinical - Inflammatory disease		Discontinued; Preclinical	Q1Q2	ASTRAZENECA PLC.	16001412	Q1Q2	1995	2015
30124349	ZD-2767D	January 13, 2016					Preclinical		CCD	Preclinical - CANCER		Preclinical	JAN16	ASTRAZENECA PLC	30124349	JAN16	1995	2016
30122784	AZD-3759	March 28, 2016					Phase II	Epidermal growth factor receptor tyrosine kinase inhibitor	CCD	Phase II - BRAIN METASTASES; Phase I - NON-SMALL CELL LUNG CANCER		Phase II; Phase I	AUG15	ASTRAZENECA	30122784	APR16	1995	2016
30122784	AZD-3759	March 28, 2016					Phase II	Epidermal growth factor receptor tyrosine kinase inhibitor	CCD	Phase II - BRAIN METASTASES; Phase I - NON-SMALL CELL LUNG CANCER		Phase II; Phase I	AUG15	ASTRAZENECA PLC	30122784	AUG15	1995	2016
30122785	AZD-6738	July 27, 2015					Phase I	ATR INHIBITOR	CCD	Phase I - Solid tumor		Phase I	AUG15	ASTRAZENECA PLC	30122785	AUG15	1995	2015
30122814	AZD-8835	July 16, 2015					Phase I	PHOSPHOINOSITIDE 3-KINASE ALPHA INHIBITOR; PHOSPHOINOSITIDE 3-KINASE DELTA INHIBITOR	CCD	Phase I - ADVANCED SOLID MALIGNANCIES		Phase I	AUG15	ASTRAZENECA PLC	30122814	AUG15	1995	2015
30122815	AZD-9496	July 21, 2015					Phase I	ESTROGEN RECEPTOR DOWN-REGULATOR; ESTROGEN RECEPTOR ALPHA ANTAGONIST	CCD	Phase I - BREAST CARCINOMA		Phase I	AUG15	ASTRAZENECA PLC	30122815	AUG15	1995	2015
30122820	MEDI-1814	July 20, 2015					Phase I		CCD	Phase I - Alzheimer's disease		Phase I	AUG15	ASTRAZENECA PLC	30122820	AUG15	1995	2015
30122821	MEDI-3902	July 20, 2015					Phase I	MEDI3902 IS A BISPECIFIC MONOCLONAL ANTIBODY THAT INHIBITS PSEUDOMONAS AERUGINOSA TYPE 3 SECRETION MEDIATED CYTOTOXICITY AND PROMOTES OPSONOPHAGOCYTIC KILLING OF THE BACTERIUM BY TARGETING THE T3S PCRV PROTEIN AND THE PSL EXOPOLYSACCHARIDE	CCD	Phase I - NOSOCOMIAL PNEUMONIA		Phase I	AUG15	ASTRAZENECA PLC	30122821	AUG15	1995	2015
30122822	MEDI-4893	July 21, 2015					Phase II	MEDI4893 IS AN IMMUNOGLOBULIN G MONOCLONAL ANTIBODY THAT SPECIFICALLY BINDS TO AND NEUTRALISES ALPHA TOXIN, A STAPHYLOCOCCUS AUREUS VIRULENCE FACTOR	CCD	Phase II - PNEUMONIA		Phase II	AUG15	ASTRAZENECA PLC	30122822	AUG15	1995	2015
30124883	NEO-6860	March 17, 2016					Phase II	Vanilloid receptor TRPV1 antagonist	CCD	Phase II - OSTEOARTHRITIC PAIN; Phase I - OSTEOARTHRITIC PAIN		Phase II; Phase I	APR16	ASTRAZENECA CANADA	30124883	APR16	1995	2016
30125062	AZD0156	March 28, 2016					Phase I	ATM SERINE/THREONINE KINASE INHIBITOR	CCD	Phase I - Solid tumor		Phase I	APR16	ASTRAZENECA	30125062	APR16	1995	2016
30125067	AZD7594	April 01, 2016					Phase II	Glucocorticoid receptor modulator	CCD	Phase II - ASTHMA, CHRONIC OBSTRUCTIVE PULMONARY DISEASE		Phase II	APR16	ASTRAZENECA	30125067	APR16	1995	2016
30125068	AZD7986	March 31, 2016					Phase I		CCD	Phase I - Chronic obstructive pulmonary disease		Phase I	APR16	ASTRAZENECA	30125068	APR16	1995	2016
30125069	AZD8108	March 31, 2016					Phase I	N-METHYL-D-ASPARTATE ANTAGONIST	CCD	Phase I - SUICIDAL IDEATION		Phase I	APR16	ASTRAZENECA	30125069	APR16	1995	2016
30125070	AZD8871	March 31, 2016					Phase I		CCD	Phase I - ASTHMA, CHRONIC OBSTRUCTIVE PULMONARY DISEASE		Phase I	APR16	ASTRAZENECA	30125070	APR16	1995	2016
30125071	AZD8999	April 04, 2016					Phase I	MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONIST; BETA 2 ADRENOCEPTOR AGONIST	CCD	Phase I - Chronic obstructive pulmonary disease		Phase I	APR16	ASTRAZENECA	30125071	APR16	1995	2016
30125073	AZD9567	April 04, 2016					Phase I	Glucocorticoid receptor modulator	CCD	Phase I - Rheumatoid arthritis		Phase I	APR16	ASTRAZENECA	30125073	APR16	1995	2016
30125074	AZD9977	April 01, 2016					Discontinued	Mineralocorticoid receptor modulator	CCD	Discontinued - DIABETIC KIDNEY DISEASES; Phase I - DIABETIC KIDNEY DISEASES		Discontinued; Phase I	APR16	ASTRAZENECA PLC	30125074	APR16	1995	2016
30125075	DURVALUMAB + DABRAFENIB + TRAMETINIB	April 12, 2016					Phase I		CCD	Phase I - Melanoma		Phase I	APR16	ASTRAZENECA AB	30125075	APR16	1995	2016
30125080	IRESSA + DURVALUMAB	April 11, 2016					Phase I		CCD	Phase I - Non-small cell lung cancer		Phase I	APR16	ASTRAZENECA PLC	30125080	APR16	1995	2016
30125096	TAGRISSO + DURVALUMAB	March 28, 2016					Suspended		CCD	Suspended - NON-SMALL CELL LUNG CANCER; Phase III - NON-SMALL CELL LUNG CANCER		Suspended; Phase III	APR16	ASTRAZENECA	30125096	APR16	1995	2016
30125098	TAGRISSO + SAVOLITINIB	March 29, 2016					Phase I		CCD	Phase I - Non-small cell lung cancer		Phase I	APR16	ASTRAZENECA	30125098	APR16	1995	2016
30123298	AZ-10606120	October 14, 2015					Preclinical	P2X7 RECEPTOR ANTAGONIST	CCD	Preclinical - CANCER, IMMUNE DISORDER, INFLAMMATORY DISEASE, CARDIOVASCULAR DISEASE		Preclinical	OCT15	ASTRAZENECA PLC	30123298	OCT15	1995	2015
30108520	ZD-7288	February 17, 2015					Discontinued	SINO-ATRIAL NODE FUNCTION MODULATOR	CCD	Discontinued - ANGINA PECTORIS; Phase II - ANGINA PECTORIS		Discontinued; Phase II	MAR15	ASTRAZENECA PLC.	30108520	MAR15	1995	2015
30120682	NALOXEGOL	October 13, 2014	PRESCRIPTION DRUG			The recommended dosage is 25 mg once daily in the morning. If patients are not able to tolerate, then reduce the dosage to 12.5 mg once daily.	Launched	Opioid receptor Mu antagonist	DD	Launched - OPIOID-INDUCED CONSTIPATION WITH CHRONIC NON-CANCER PAIN	September 16, 2014	Launched	OCT14_5	ASTRAZENECA	30120682	OCT14_5	2014	2014
30123946	AZD-4721	November 25, 2015		AstraZeneca has discontinued the development of AZD-4721 for the indication of chronicobstructivepulmonarydisease due to safety/efficacy.			Discontinued	C-X-C chemokine receptor 2 antagonist	CCD	Discontinued - CHRONIC OBSTRUCTIVE PULMONARY DISEASE; Phase I - CHRONIC OBSTRUCTIVE PULMONARY DISEASE		Discontinued; Phase I	DEC15	ASTRAZENECA PLC	30123946	DEC15	1995	2015
30123947	AZD-6423	December 01, 2015		The drug was discontinued due to lack of safety or efficacy.			Discontinued	NMDA receptor antagonist	CCD	Discontinued - SUICIDAL IDEATION; Phase I - SUICIDAL IDEATION		Discontinued; Phase I	DEC15	ASTRAZENECA	30123947	DEC15	1995	2015
30120786	OMEGA-3-CARBOXYLIC ACIDS	January 08, 2015	PRESCRIPTION DRUG			The dosage of EPANOVA is 2 grams (2 capsules) or 4 grams (4 capsules) once daily.	Launched	POTENTIAL MECHANISMS OF ACTION INCLUDE INHIBITION OF ACYL-COA:1,2-DIACYLGLYCEROL ACYLTRANSFERASE, INCREASED MITOCHONDRIAL AND PEROXISOMAL BETA-OXIDATION IN THE LIVER, DECREASED LIPOGENESIS IN THE LIVER, AND INCREASED PLASMA LIPOPROTEIN LIPASE ACTIVITY.	DD	Launched - HYPERTRIGLYCERIDEMIA	May 05, 2014	Launched	JAN15_5	ASTRAZENECA PLC	30120786	JAN15_5	2014	2015
30118064	MEDI-557	November 11, 2014					Discontinued		CCD	Phase I - RESPIRATORY SYNCYTIAL VIRUS INFECTION; Discontinued - RESPIRATORY SYNCYTIAL VIRUS INFECTION		Discontinued; Phase I	NOV14_4	ASTRAZENECA PLC	30118064	NOV14_4	1995	2014
30123295	ARC-155858	September 30, 2015					Preclinical	MONOCARBOXYLATE TRANSPORTER-1 INHIBITOR; MONOCARBOXYLATE TRANSPORTER-2 INHIBITOR	CCD	Preclinical - Immunosuppression		Preclinical	NOV15	ASTRAZENECA PLC	30123295	NOV15	1995	2015
30120892	AZD-7507	February 06, 2015					Preclinical	Colony stimulating factor 1 receptor inhibitor	CCD	Preclinical - CANCER		Preclinical	FEB15	ASTRAZENECA PLC	30120892	FEB15	1995	2015
30120921	AZD-8186	February 03, 2015					Phase I	PHOSPHOINOSITIDE 3-KINASE BETA INHIBITOR; PHOSPHOINOSITIDE 3-KINASE DELTA INHIBITOR	CCD	Phase I - TRIPLE-NEGATIVE BREAST CANCER, CASTRATE RESISTANT PROSTATE CANCER, SQUAMOUS NON-SMALL CELL LUNG CANCER		Phase I	FEB15	ASTRAZENECA PLC	30120921	FEB15	1995	2015
30120922	AZD-9291	November 16, 2015	PRESCRIPTION DRUG			The recommended dose of TAGRISSO is 80 mg orally once daily, with or without food.	Launched	EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITOR	CCD	Launched - NON-SMALL CELL LUNG CANCER; Phase III - NON-SMALL CELL LUNG CANCER; Phase II - NON-SMALL CELL LUNG CANCER; Phase I - NON-SMALL CELL LUNG CANCER	November 13, 2015	Launched; Phase III; Phase II; Phase I	FEB15	ASTRAZENECA PLC	30120922	FEB15	2015	2015
30120923	AZD-7624	January 27, 2015					Phase II	p38 MAP kinase inhibitor	CCD	Phase II - Chronic obstructive pulmonary disease		Phase II	FEB15	ASTRAZENECA PLC	30120923	FEB15	1995	2015
30120952	ESOMEPRAZOLE MAGNESIUM + NAPROXEN	January 21, 2015	PRESCRIPTION DRUG			One tablet twice daily contain (375 mg/20 mg or 500 mg/20 mg) of naproxen and esomeprazole magnesium	Launched		DD	Launched - OSTEOARTHRITIS, RHEUMATOID ARTHRITIS, ANKYLOSING SPONDYLITIS	April 30, 2010	Launched	FEB15	ASTRAZENECA PLC.	30120952	FEB15	2010	2015
30125061	AZTREONAM + AVIBACTAM	April 25, 2016					Phase II		CCD	Phase I - BACTERIAL INFECTION; Phase II - COMPLICATED INTRA-ABDOMINAL INFECTION		Phase I; Phase II	MAY16	ASTRAZENECA PLC	30125061	MAY16	1995	2016
30125065	AZD5069 + DURVALUMAB	April 18, 2016					Phase II		CCD	Phase II - SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK		Phase II	MAY16	ASTRAZENECA	30125065	MAY16	1995	2016
30125079	EPANOVA + DAPAGLIFLOZIN	April 18, 2016					Phase II		CCD	Phase II - Non-alcoholic steatohepatitis		Phase II	MAY16	ASTRAZENECA AB	30125079	MAY16	1995	2016
30125082	LESINURAD + ALLOPURINOL	May 03, 2016					Phase I		CCD	Phase I - GOUT		Phase I	MAY16	ASTRAZENECA PLC	30125082	MAY16	1995	2016
30125097	TAGRISSO + SELUMETINIB	April 18, 2016					Phase I		CCD	Phase I - Non-small cell lung cancer		Phase I	MAY16	ASTRAZENECA	30125097	MAY16	1995	2016
30121008	ASPIRIN + ESOMEPRAZOLE	February 05, 2015	PRESCRIPTION DRUG			1 capsule once daily.	Launched		DD	Launched - CARDIOVASCULAR DISEASE, CEREBROVASCULAR DISEASE	August 02, 2011	Launched	FEB15	ASTRAZENECA PLC	30121008	FEB15	2011	2015
30125076	DURVALUMAB + MEDI0680	May 31, 2016					Phase I		CCD	Phase I - Solid tumor		Phase I	JUN16	ASTRAZENECA PLC	30125076	JUN16	1995	2016
30125077	DURVALUMAB + MEDI6383	May 31, 2016					Phase I		CCD	Phase I - Solid tumor		Phase I	JUN16	ASTRAZENECA PLC	30125077	JUN16	1995	2016
30005879	FPL-52694	January 21, 2015					Phase I	Mast cell stabiliser	CCD	Phase I - DUODENAL ULCER		Phase I	FEB15	ASTRAZENECA PLC	30005879	FEB15	1995	2015
30005899	NCQ-298	February 04, 2015					Preclinical	Dopamine receptor D2 antagonist	CCD	Preclinical - Diagnostic imaging		Preclinical	FEB15	ASTRA RESEARCH CENTRE AB	30005899	FEB15	1995	2015
30005237	ZD-6021	October 28, 2014					Preclinical	NK1 RECEPTOR ANTAGONIST; NK2 RECEPTOR ANTAGONIST	CCD	Preclinical - Asthma		Preclinical	NOV14_4	ASTRAZENECA	30005237	NOV14_4	1995	2014
30107983	ICI-197067	November 05, 2014					Preclinical	Kappa opioid receptor agonist	CCD	Preclinical - PAIN, DIURESIS		Preclinical	NOV14_4	ASTRAZENECA	30107983	NOV14_4	1995	2014
30122667	AZD-0914	August 24, 2015					Phase II	DNA gyrase inhibitor	CCD	Phase II - GONORRHEA; Preclinical - CHLAMYDIAL INFECTION, MYCOPLASMA INFECTION		Phase II; Preclinical	SEP15	ASTRAZENECA PLC	30122667	SEP15	1995	2015
30122783	MEDI-8111	September 07, 2015					Phase I	COAGULATION FACTOR MODULATOR	CCD	Phase I - TRAUMA, BLEEDING		Phase I	SEP15	ASTRA ZENECA PLC	30122783	SEP15	1995	2015
30122430	ZM-336372	June 24, 2015					Preclinical	c-RAF inhibitor	CCD	Preclinical - CANCER		Preclinical	JUL15	ASTRAZENECA PLC	30122430	JUL15	1995	2015
30122431	ZM-449829	June 09, 2015					Preclinical	Jak3 tyrosine kinase inhibitor	CCD	Preclinical - Bacterial Infection		Preclinical	JUL15	ASTRAZENECA PLC	30122431	JUL15	1995	2015
30127821	MMV253	December 05, 2016					Preclinical		CCD	Preclinical - Malaria		Preclinical	DEC16	ASTRAZENECA PLC	30127821	DEC16	1995	2016
30128026	MEDI-0562 + TREMELIMUMAB	December 06, 2016					Phase I		CCD	Phase I - Solid tumor		Phase I	DEC16	ASTRAZENECA	30128026	DEC16	1995	2016
30127362	AR-C165395XX	September 13, 2016					Phase I		CCD	Phase I - Type-2 diabetes		Phase I	OCT16	ASTRAZENECA	30127362	OCT16	1995	2016
30125088	RITUXIMA + MEDI551	August 24, 2016					Discontinued		CCD	Phase I - HEMATOLOGICAL MALIGNANCY; Preclinical - B-CELL LYMPHOMA; Discontinued - HEMATOLOGICAL MALIGNANCY		Discontinued; Phase I; Preclinical	SEP16	ASTRAZENECA	30125088	SEP16	1995	2016
30126057	AZD-9412	June 14, 2016					Phase II		CCD	Phase II - ASTHMA; Phase I - CHRONIC OBSTRUCTIVE PULMONARY DISEASE		Phase II; Phase I	JUL16	ASTRAZENECA	30126057	JUL16	1995	2016
30126200	AZD2811	June 30, 2016					Phase I	Aurora kinase B inhibitor	CCD	Phase I - SOLID TUMOR, SMALL CELL LUNG CANCER, HEMATOLOGICAL CARCINOMA		Phase I	JUL16	ASTRAZENECA	30126200	JUL16	1995	2016
30128025	MEDI-0562 + DURVALUMAB	October 24, 2016					Phase I		CCD	Phase I - Solid tumor		Phase I	NOV16	ASTRAZENECA PLC	30128025	NOV16	1995	2016
30126526	MEDI7352	August 04, 2016					Phase I		CCD	Phase I - OSTEOARTHRITIC PAIN		Phase I	AUG16	ASTRAZENECA PLC	30126526	AUG16	1995	2016
